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Abstract 
Purpose: To predict the risk of radiation necrosis in a cohort of pediatric patients with 
glioma and ependymoma and compare the predicted risk between volumetric modulated 
arc photon therapy (VMAT), passively scattered proton therapy (PSPT) and intensity 
modulated proton therapy (IMPT). 
Methods: Thirteen pediatric patients with varying age and sex were selected for this 
study. A radiation oncologist contoured a clinical treatment volume (CTV) on 8 patients 
selected for glioma in the cerebral hemisphere and 5 with ependymoma located in the 
posterior fossa. A 1 cm margin was added to the CTV to define the planning treatment 
volume (PTV). VMAT plans were constructed using Phillips Pinnacle treatment planning 
system. PSPT and IMPT plans were constructed using Varian Eclipse. Plans were 
compared using several dose metrics to ensure consistency between plan coverage. 
Normal tissue complication probability (NTCP) with radiation necrosis as an endpoint 
was calculated using the Lyman Kutcher Burman probit model. The ratio of risk was 
calculated between protons and photons and compared to a value of 1 using the student t-
test and Wilcoxon signed rank test. Sensitivity tests were performed to determine if the 
predicted risk of necrosis was sensitive to positional errors, proton range errors and 
selection of risk models.  
Results: PSPT plans resulted in an average ratio of risk of 0.44 (p<0.00001) and 0.62 
(p<0.02) for glioma and ependymoma patients compared to VMAT respectively. IMPT 
plans resulted in an average ratio of risk of 0.33 (p<0.00001) and 0.32 (p<0.00001) for 
glioma and ependymoma plans compared to VMAT respectively.  
 xv 
Conclusion: Both PSPT and IMPT plans statistically significantly reduced the predicted 
risk of radiation necrosis using the LKB NTCP risk model. Sensitivity analysis upheld 
these qualitative findings. 
 1 
Chapter 1 : Introduction 
1.1 Background 
Cancer of the brain and central nervous system (CNS) is the second most common of 
all pediatric cancers. At a rate of 5.1 out of every 100,000 cases per year, its incidence is 
second only to leukemia and there are approximately 4300 new cases of primary 
malignant and non-malignant brain and CNS tumors expected every year within the 
United States (Dolecek et al., 2012). Due to improved medical techniques, the cure rate 
for these diseases has steadily increased. The research focus has shifted to disease and 
treatment related side effects. The focus of this work is to compare the predicted risks of 
radiation-induced necrosis of the brain using several contemporary types of radiotherapy. 
1.2 Pediatric Brain Cancer Epidemiology 
The Surveillance Epidemiology and End Result (SEER) program reported that 
astrocytomas make up 52% of pediatric brain cancers, followed by Primitive 
Neuroectodermal Tumors (PNET) (21%), other gliomas (15%) and Ependymomas (9%) 
(Ries et al., NIH Pub. No. 99-4649). These main types of pediatric brain tumors are 
broadly classified as tumors of the neuroepithelial tissue because of their involvement of 
the epithelium or covering of the external surface of the nerves (Louis et al., 2007). These 
tumor types can further be classified by their grade and location in the brain.  Cerebral 
tumors are those that the primary tumor site is located above the cerebellar tentorium.  
The tentorium is an extension of the dura mater into the space between the cerebellum 
and the inferior occipital lobes in the brain. Cerebral tumors are supratentorial because 
they are located above this demarcation, whereas cerebellar tumors are infratentorial 
because the primary tumor lies within the cerebellum in the posterior fossa.  
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Astrocytomas are a type of glioma that arise in the astrocyte cells of the brain 
(Halperin et al., 2010). A majority of these tumors in children are pilocytic astrocytomas 
which are considered low grade by the World Health Organization (WHO) grading 
system, and will not spread far from the primary tumor site (Pizzo and Poplack, 1997). 
These low-grade pilocytic astrocytomas can be found supratentorially in the brain or 
infratentorially in the cerebellum. High-grade astrocytomas such as anaplastic 
astrocytoma (WHO grade III) and glioblastoma (WHO grade IV) are less common 
among children and are typically found supratentorially (Pizzo and Poplack, 1997; Louis 
et al., 2007). 
PNET is a broad classification of tumors that involve the neuroectoderm of the brain.  
This tumor classification includes neuroblastoma, pineoblastoma and medulloblastoma, 
although medulloblastomas comprise more than half of the primitive neuroectodermal 
tumors that are seen in pediatrics (De Laney and Kooy, 2008). Medulloblastomas are 
often found medially in the cerebellum in a region known as the vermis that resides in the 
posterior fossa of the cranium. Medulloblastoma is one of the most common malignant 
primary brain tumors in pediatrics and has a tendency to seed new tumors via the 
cerebrospinal fluid requiring radiation treatments of the entire craniospinal cavity (De 
Laney and Kooy, 2008; Pizzo and Poplack, 1997). 
Ependymomas are a type of tumor that occur in the ependymal cells of the CNS.  In 
children a majority of these occur intercranially within the posterior fossa in the lining of 
the 4th cerebral ventricle (Pizzo and Poplack, 1997; De Laney and Kooy, 2008; Schild et 
al., 1998). Although most are infratentorial in children they can occur supratentorially or 
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spread contiguously above the tentorium or into adjacent brain tissue (Pizzo and Poplack, 
1997). 
1.3 Standards of Care 
Standards of care for selected pediatric brain cancers considered in this work will be 
discussed for proton and photon radiotherapies in this section. 
1.3.1 Astrocytoma 
1.3.1.1 Low Grade 
Most of the low-grade gliomas that are located supratentorially in children are 
astrocytomas.  Treatment for these tumors often depends on the amount of surgical 
resection that can be achieved. If gross total resection can be achieved, then many times 
no other treatment may be necessary.  If the tumor cannot be completely resected, then 
radiation therapy and/or chemotherapy may be used(Pizzo and Poplack, 1997). 
When radiation therapy is used the typical prescription is 50-60 Gy in 1.8-
2Gy/fraction to the Gross Tumor Volume (GTV) plus a geometric expansion of 2 cm to 
account for subclinical disease and patient setup error (Pizzo and Poplack, 1997). 
1.3.1.2 High grade 
High-grade anaplastic astrocytomas are typically seen in the cerebral hemispheres in 
children.  Due to the aggressive nature of these tumors gross total resection is often not 
possible due to the danger of increased neurological morbidity (Pizzo and Poplack, 
1997).  Often surgery is followed by radiation therapy to a dose of 50-60 Gy in 1.8-2 
Gy/fraction to the GTV plus a geometric expansion of 2-4 cm (Pizzo and Poplack, 1997). 
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1.3.2 Ependymoma 
Ependymomas are often located infratentorially, making gross total resection 
much more difficult due to the proximity of the brainstem (Halperin et al., 2010). Most 
often, surgery is followed by radiation therapy.  For photon therapy, the prescription is 
typically 50-55 Gy in 1.8-2 Gy/fraction to the planned treatment volume (PTV) which 
includes the GTV plus a geometric expansion of 1-2 cm (Halperin et al., 2010). Proton 
therapies have been administered up to 59.4 Gy-RBE to the PTV which includes the 
GTV plus 2-5 cm expansion (De Laney and Kooy, 2008). 
1.4 Side Effects of Radiotherapy 
The potential risk of injury from CNS irradiation can include acute effects and 
late effects.  Acute affects are seen early and can include alopecia, erythema, otitis, 
tinnitus, or even temporary demyelination (Pizzo and Poplack, 1997). Alternatively late 
effects onset more than 6 months after treatment, tends to be more severe and include 
spinal myelopathy, endocrine and cognitive dysfunction, secondary cancers, and radiation 
induced necrosis (Haas-Kogan et al., 2010). With approximately 72% and 73% five-year 
survival rate after treatment of patients with primary brain and CNS tumors between the 
ages 0-14 and 0-19, respectively, the risk of late effects when treating pediatric patients 
with radiation is a major concern (Ostrom et al., 2013).  The primary focus of this 
investigation is to predict the risk of the late effect of radiation-induced necrosis. 
1.5 Radiation necrosis 
Radiation induced necrosis (RIN) is a late effect that can have a latency of as little 
as 3 month or as long as 13 year after treatment (Fink et al., 2012). Little is known about 
the mechanism by which radiation-induced necrosis occurs but it has been suggested by 
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Fink et al. (2012) that it may be a result of ischemia resulting from vascular endothelial 
injury or from the loss of or injury to oligodendrocytes. Due in part to a long latency, 
difficulty of diagnosis, and apparently low incidence, the true incidence of RIN is poorly 
known (Chao et al., 2013). Some reports indicate that depending on the treatment 
protocol the actual incidence could be anywhere from 3-24% (Ruben et al., 2006).  
Necrosis varies in severity from asymptomatic radiographic changes, cognitive 
dysfunction, stroke to death. Current treatments include surgery, corticosteroids, 
anticoagulants, hyperbaric oxygen therapy, laser interstitial thermal therapy and VEGF 
inhibitors (Bennett et al., 2005; Ashamalla et al., 1996; Chuba et al., 1997; Delanian and 
Lefaix, 2007; Gonzalez et al., 2007; Wong et al., 2008; Whelan and Helms, 2012). 
Treatment of necrosis is, at most, effective in treating the symptoms but to date little has 
done to treat the cause of necrosis. Additionally some of the mostly widely used 
treatments, such as corticosteroids, have risks associated with prolonged use and others 
have too few studies to support their widespread use or have been shown to have little 
effect (Delsigne, 2012; Bennett et al., 2012). 
Although there are many unknowns, we do know that risk of necrosis is 
associated with the total dose that is given to the patient, the total volume irradiated, and 
the fraction size (Lawrence et al., 2010; Lee et al., 1998; Fink et al., 2012; Murphy et al., 
2012). Other potential risk factors include concurrent chemotherapy, age at exposure, 
treatment modality, etc. (Lee et al., 2011; Lawrence et al., 2010). To date little has been 
done to explore the difference between photon and proton treatment modalities and their 
effect on risk reduction for radiation necrosis as an endpoint.  
 6 
Recent retrospective studies have assessed some of these risk parameters. A 
recent study on the quantitative analysis of normal tissue effects in the clinic 
(QUANTEC) looked at the radiation dose-volume effects in the brain (Lawrence et al., 
2010).  Their result indicates that the dose to cause radiation is high with a predicted 5% 
and 10% risk of symptomatic necrosis to occur at 72 Gy and 90 Gy given in 2 
Gy/fraction increments (Lawrence et al., 2010).  Additionally they added that fractions 
sizes greater than 2 Gy increased the risk.  Another recent study by Murphy et al. (2012) 
found that the percentage of the infratentorial brain receiving 50, 52 and 54 Gy were 
significant predictors of risk for necrosis for pediatric being treated for 
craniopharyngioma. Also Ruben et al. (2006) found that the risk of necrosis increases 
with increasing dose, fraction size and the addition of chemotherapy.  
All of the above studies were based on patients treated with photon therapy. 
Boehling et al. (2012) compared intensity modulated photon therapy (IMRT) with 
intensity modulated proton therapy (IMPT) for pediatrics with craniopharyngioma and 
found IMPT spared dose to the cerebral vasculature compared to IMRT. Other studies 
have found similar effects of normal tissue sparing for pediatric medulloblastoma when 
comparing passively scattered proton therapy (PSPT) to conventional photon therapy 
(Howell et al., 2012). 
1.6 Significance and Objective 
Although the expected incidence of radiation-induced necrosis may be low it is a severe 
and potentially lethal late effect that can extremely impact these patients quality of life. 
Volumetric modulated arc therapy (VMAT) is a rotational arc photon therapy that can 
provide a highly conformal dose to the tumor but also increase the volume of normal 
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tissue surrounding the treatment area that receives low dose (Myrehaug et al., 2012; Qi et 
al., 2012). Passively scattered (PSPT) and intensity modulated proton therapy (IMPT) 
can also provide highly conformal dose distributions but reduce the volume of brain 
tissue receiving low dose (Boehling et al., 2012). However, due to competing dose 
heterogeneity effects that are often seen in proton therapy there may be significant 
hotspot formation (Urie et al., 1984). These competing dose and volume effects are not 
well understood and need to be better quantified. To date there have been no studies 
comparing the effectiveness of Volumetric modulated arc photon therapy to passively 
scattered and intensity modulated protons therapy to reduce the predicted risk of necrosis 
in pediatrics following radiation. The objective of this study is to predict the ratio of risk 
of radiation-induced necrosis in a cohort of pediatric patients between VMAT and PSPT 
and between VMAT and IMPT. 
1.7 Hypothesis 
Due to the reduction in irradiated volume that protons confer and additional dose 
inhomogeneities that may result in hotspot formation we hypothesized that: For a 
clinically representative cohort of pediatric brain cancer patients, passively scattered and 
intensity modulated proton therapy plans will offer no statistical difference in the 
predicted risk of radiation-induced necrosis of the brain using existing risk models 
compared to VMAT. 
To test this hypothesis, we performed the following specific aims: 
Aim 1: Evaluate and compare VMAT, PSPT and IMPT plans on the basis of dosimetric 
endpoints for the PTV and whole brain. 
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Aim 2: Predict the risk of radiation necrosis incidence for VMAT, PSPT and IMPT plans 
for the cohort of pediatric patients using existing risk models to determine if the relative 
risk is statistically significantly different between treatment modalities. 
Aim 3: Perform sensitivity analysis to determine if the baseline risk is dependent on setup 
error, proton range uncertainties and selection of risk model. 
  
 9 
Chapter 2 : Methods 
2.1 Aim 1 – Design and Evaluation of Radiation Treatment Plans 
2.1.1 Patient Sample 
A patient database was constructed with 13 anonymized CT data sets from 
pediatric patients with varying age, sex and treatment sites. These patients were 
consecutively sampled from patients that were previously treated with proton CSI at the 
University of Texas at M.D. Anderson between 2007 and 2009. Inclusion criteria were 
that patients be between 2 and 16 years old at the time of treatment. Exclusion criteria 
were severe edema from the original CSI treatment and/or the insertion of a stint. Five of 
these patients were used for our ependymoma comparison and 8 for the astrocytoma 
(glioma) comparison. A list of these patients based on age, sex and disease type can be 
seen in Table 2.1.  
Table 2.1 Patient index, age, sex and diagnosis used for the study 
Patient 
index 
Age at 
treatment Sex 
Assigned 
Diagnosis* 
1 2 F Glioma 
2 4 M Glioma 
3 6 F Glioma 
4 8 F Glioma 
5 10 F Glioma 
6 4 M Glioma 
7 6 M Glioma 
8 8 M Glioma 
9 10 M Ependymoma 
10 12 F Ependymoma 
11 13 F Ependymoma 
12 16 F Ependymoma 
13 16 F Ependymoma 
*Note: Diagnoses were assigned were assigned for the purposes of this study and were 
different from the diagnoses listed in the medical records  
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2.1.2 Contouring of Target Volume and Healthy Tissue 
Contouring was performed in Phillips Pinnacle treatment planning system.  A 
clinical treatment volume (CTV) was created for each patient by the same board certified 
radiation oncologist to represent the glioma and ependymoma gross tumor volume (GTV) 
plus any subclinical disease that may exist. An additional 1 cm margin was then added to 
the CTV to define the planned treatment volume (PTV). This additional PTV margin 
accounts for patient setup error. A PTV reduction of no more than 0.5cm was allowed to 
account for organs at risk or boney anatomy.  
Additional contours included a partial brain contour that was constructed by 
subtracting the PTV plus an additional 1 cm margin from the brain contour.  This 
structure was used in plan optimization.  Other contours used for treatment planning 
included the brainstem, optic chiasm, optic nerve, spinal cord, eyes, and lens of the eye.  
These structures were used for each patient across all planning modalities for 
consistency. 
2.1.3 Treatment Plans 
A prescription dose of 54 Gy in 1.8 Gy/fraction over 30 fractions was used for all 
patients. Plans were considered provisionally acceptable when the dose to 95% of the 
PTV (D95%) was 95% (51.3 Gy) of the prescription for glioma plans and 90% (48.6 Gy) 
for ependymoma plans.  These dose objectives were maintained unless the constraint for 
the optic chiasm (50 Gy) or brainstem (54 Gy) was not met. Some other organs at risk 
and their dose tolerance limits can be seen in Table 2.2. 
The relative biological effect (RBE) of Protons is greater than that of photons. 
The mean relative biological effectiveness (RBE) of protons between the energies of 60 
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MeV and 250 MeV is 1.1 as reported by ICRU report 78. This generic value of 1.1 is 
recommended by ICRU report 78 to account for the increase in RBE when reporting 
proton dose. This convention was used in our proton plans and dose reported in this 
research were assigned the unit Gray-RBE (Gy-RBE). Gy-RBE was also used to report 
photons dose. This convention for photons was used for simplicity of reporting units and 
equivalent to dose of photons in Gray (Gy) assuming an RBE of one compared to 
protons.  
Table 2.2 Normal tissue radiation tolerance for pediatrics for various organs at risk 
(Haas-Kogan et al., 2010; Hall and Giaccia, 2012). 
Structure Late Effect Pediatric 
Threshold Dose 
Spinal cord Chronic progressive 
myelitis 
45 Gy 
Brain Radiation necrosis 
Intellectual deficits 
54 Gy 
12-18 Gy 
Lens of eye Cataract formation 6 Gy 
Retina Radiation 
retinopathy 
30-35 Gy 
Optic nerve Optic neuritis 50 Gy 
Inner ear Sensorineural 
hearing loss 
40-50 Gy 
Brainstem Necrosis 54 Gy 
 
2.1.3.1 Photon Plans 
Volumetric Modulated Arc Therapy (VMAT) was selected for this study due to 
the increased dose conformity and the age of the patients that have to undergo radiation 
therapy. Although our patient demographic had some adolescent (12-16y), younger 
patients would likely require anesthesia during treatment for immobilization. VMAT 
offers a reduction in the treatment time need to deliver a highly conformal dose to the 
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treatment volume and therefore the time that the pediatric patient will have to spend 
under anesthesia (Otto, 2008).  
The use of VMAT gives us the ability to vary the arc angle through which the 
patient gets treated.  The selection of a partial arc vs. a full 360-degree arc was 
determined by the location of the PTV isocenter, coverage of the PTV and reduction of 
dose in the surrounding brain.  For all patients, full arc and partial arc plans were created.  
If the tumor was non-centrally located within the brain, PTV coverage could typically be 
achieved with 2 partial arcs up to 225 degrees per arc. Additionally this setup would 
reduce the extra brain dose.  If good PTV coverage could not be achieved then a full was 
selected for treatment. 
Most of the glioma patients had non-centrally located tumors and were planned 
with 2 partial arcs.  For gliomas located in the right cerebral hemisphere typical start and 
stop angles were 45 and 181 degrees, respectively, starting with a counter clockwise 
rotation followed by a clockwise rotation and where a gantry angle of zero refers to the 
gantry position at top center. For patient 7, who had a glioma located in the left cerebral 
hemisphere, the gantry rotated counter clock wise from 179 degrees to 320 degrees.   
Ependymoma patients had treatment volumes that were centrally located and 
good PTV coverage could not be achieved with a partial arc. All of these patients were 
planned using a full arc rotating counter clock wise from 179 degrees to 181 degrees.  
The selection of 6 MV beam energy for VMAT plans was based on several 
factors.  Several studies have shown that there is little benefit to using higher beam 
energies (Pasler et al., 2011). Additionally, with beam energies of 10 MV and greater, 
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photonuclear interactions lead to unwanted neutron contamination in the beam and 
additional dose to the patient (Attix, 2007). For this reason, 6MV was used in all cases.  
For both partial and full arc treatments the partial brain contour was used to help 
optimize VMAT plans. In many ways this is the same as creating a “ring” structure 
surrounding the PTV to achieve a sharper dose falloff outside of the PTV and increase 
conformity within the PTV. An example of the partial brain structure can be seen in 
Figure 2.1. 
 
Figure 2.1. The partial brain contour, shown in orange colorwash, surrounds the PTV 
shown in red color wash with an additional 1 cm margin (shown as grey brain tissue). 
This contour was used for VMAT optimization to reduce the dose to the normal brain 
tissue surrounding the PTV and achieve a sharper dose fall off outside of the PTV.  
The parameters for VMAT dose optimization can be seen in Table 2.3 These 
objectives were set at or below the dose threshold limits for organs at risk listed in Table 
2.2. After an initial VMAT optimization was run the criteria were adjusted until an 
provisionally acceptable plan was produced. 
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The criteria for acceptability were based on the dose to the PTV as well as the 
organs at risk (OAR).  These criteria differed for disease type and was set to D95% = 95% 
for the glioma PTV and D95% = 90% for the ependymoma PTV. Additionally the 
brainstem and optic chiasm where set as dose constraints so that the dose to these 
structures was limited even if the dose to the PTV suffered. Final acceptability of the 
plans was determined according to an assessment by a board certified radiation 
oncologist based on the standard-of-care evaluation methods and subjective judgment. 
The provision plans were modified, if needed, until final acceptance by the radiation 
oncologist. The workflow for VMAT planning can be seen in Figure 2.2. 
Table 2.3 Initial optimization parameters for VMAT and IMPT plans. The objective 
represents a limit. Max Dose is a upper limit of dose that the planning system optimizes 
to stay below for the entire structure. Max DVH is an upper limit for a dose that the 
planning system optimizes to stay below for the specified percentage of the volume. The 
weighting is the preference given to the specified objective for optimization 
Region of 
interest Objective Dose (Gy) 
Volume 
(%) Weighting 
PTV Max Dose 56.7 0 90 
 
Uniform 
Dose 54.0 100 90 
Brain Stem Max Dose 54.0 0 8 
 
Max DVH 25.0 25 3 
Optic 
Chiasm Max Dose 40.0 0 1 
 
Max DVH 30.0 50 1 
Lt. Optic 
Nerve Max Dose 28.0 0 1 
 
Max DVH 12.0 15 1 
Rt. Optic 
Nerve Max Dose 28.0 0 1 
 
Max DVH 12.0 15 1 
Spinal Cord Max Dose 3.0 0 1 
Lt. Eye Max Dose 18.0 0 1 
Rt. Eye Max Dose 18.0 0 1 
Lt. cochlea Max Dose 40.0 0 1 
Rt. cochlea Max Dose 40.0 0 1 
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Figure 2.2. VMAT treatment planning workflow. 
 
2.1.3.2 Proton Treatment Plans 
Patients were planned using protons with the passively scattered technique and 
intensity modulated technique. Passively scattered proton therapy (PSPT) employs the 
use of a beam spreader and of a range compensator.  The field is conformed laterally by a 
block made of brass and the distally using a compensator that is milled out of lucite to 
conform to the distal surface of the treatment volume. Intensity modulated proton therapy 
(IMPT) is a form of dynamic beam delivery using multiple beams	  angles to deliver a 
highly conformal dose to the PTV. Dynamic beam delivery incorporates the use of 
scanning magnets to deflect a pencil beam of protons and deliver a single spot of dose to 
a desire location within the PTV. This is repeated spot by spot in layers across the PTV 
until the desired uniform dose is delivered to the entire treatment volume. 
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2.1.3.2.1 Passively Scattered Proton Therapy (PSPT) Treatment Plans 
Passively scattered proton therapy plans, in most cases, were planned using a 
single field using the double scatter technique. The benefit of using a single field was to 
reduce dose to surrounding normal brain tissue while still offering adequate PTV 
coverage. In circumstances where PTV coverage was not adequate, more than one beam 
was used to attain adequate coverage. Beam angle for PSPT varied from plan to plan and 
were dependent on the location of the tumor as well as other factors such as normal 
incidence with patient boney anatomy, reduction of heterogeneities within the beam line, 
reduction of critical structures within the beam line and reduction of excess brain tissue 
irradiatied.   
 After beam angles were set additional beam specific proximal margins (PM) and 
distal margins (DM) had to be determined due to range uncertainties inherent in proton 
beam therapy (Li, 2012).  Equations (1) and (2) were used in accordance with previously 
defined techniques by Moyers et al. (2001) for approximating the additional margins with 
respect to the CTV.  
DM on CTV = [(3.5% x distal CTV depth) + 3 mm]   (1) 
PM on CTV = [(3.5% x (proximal CTV depth) + 3 mm]  (2) 
where the 3.5% change is to account for conversion of the Hounsfield unit to proton 
stopping power and the additional 3mm accounts for the inaccuracies in the proton 
planning algorithm 
 For lateral margins the double scattering technique employs the use of a block or 
collimator.  This collimator is constructed from a piece of brass that is milled to match 
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the desired target shape. An example of this aperture can be seen in Figure 2.3. Equation 
(3) was used to determine the initial additional aperture margin. 
Lateral Margin = PTV margin + 95%-50% Penumbra  (3) 
where an additional margin is added to the PTV margin to account for the 95%-50% 
beam penumbra. In most cases this additional margin was small  (4 mm or less) and the 
plans were checked for adequate lateral dose coverage 
 
Figure 2.3 Proton collimator with custom milled aperture. (Varian Medical Systems) 
 
A range compensator achieved distal coverage of the passive scattered proton 
plans.  The range compensator is typically made from Lucite and is milled to differential 
depths depending on the distal shape of the PTV.  An example of a range compensator 
can be seen in Figure 2.4.  The purpose of the range compensator is to reduce the proton 
beam energy in regions where the compensator is thicker and less in regions where it is 
thinner, thereby changing the range of the protons beam to conform to the distal edge of 
the PTV. A smearing of 13-14 mm was used to account for patient misalignment and to 
account for any motion during treatment. This value defaults to the compensator margin 
and was not changed during planning. A border smoothing value of 1 cm was used for 
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planning. This default value is recommended to ensure that steep gradients below the 
compensator edge are avoided in order to reduce large dose gradients at the field edge. 
 
 
Figure 2.4. Lucite proton range compensator (Varian Medical Systems). 
 
 
Figure 2.5. PSPT planning workflow. 
 
After the beam line was configured with the collimator and compensator, the plan 
dose was calculated.  Additional edits were made to the compensator by adding or 
removing material to try and attain adequate distal and lateral coverage of the PTV. In 
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certain situations distal blocking was added to reduce the dose to critical structures distal 
to the PTV. Distal blocking reduces the initial distal margin assigned to the plan and 
increases the compensator thickness in the designated region, thereby reducing the 
penetration range of the protons within the patient. As with the VMAT plans initial 
acceptance was based on the dose to the PTV as well as critical structures. Once PTV 
coverage and critical structure dose constraints were met, plans were submitted for final 
approval to a radiation oncologist. The planning workflow for double scattered proton 
plans can be seen in Figure 2.5 
2.1.3.2.2 Intensity Modulated Proton Therapy (IMPT) Treatment Plans 
Intensity modulated proton plans used the same PTV and CTV as the VMAT and 
passive scattered proton plans. For most patients a 3-beam IMPT plan was constructed to 
ensure adequate distal, proximal, and lateral coverage of the PTV. This 3 beams 
arrangement in general was composed of a right lateral beam, a left lateral beam and  a 
posterior/anterior (PA) beam. However the angles of the beams were allowed to vary to 
some degree to ensure that the beam was en face, to reduce beam line heterogeneities and 
for critical structure avoidance (brainstem, optic chiasm, etc.)  
Additional margins to account for proton range uncertainties for IMPT on a beam 
by beam basis cannot currently be achieved in the Varian Eclipse v11.0 treatment 
planning system. Additionally, there is no good technique in IMPT to account for these 
uncertainties on a beam by beam basis (Hoppe et al., 2010).  Therefore, either no 
additional distal and proximal margin is added or a uniform expansion of the PTV was 
necessary to account for additional distal and proximal margins for all beams.  In this 
research, IMPT plans were assessed to determine the necessity for a uniform expansion to 
account for range uncertainty. PTV coverage was determined to be acceptable based on 
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our 3 beam arrangement and no additional margins were added to account for proton 
range uncertainty. 
Initial optimization of IMPT plans was the same as VMAT. A list of the initial 
optimization parameters can be found in Table 2.3.  After initial optimization was 
performed these parameters were adjusted to reduce the dose to critical avoidance 
structure without sacrificing plan acceptability.  After plans were considered 
provisionally acceptable they were submitted to the radiation oncologist for final 
approval.  
 
Figure 2.6. IMPT planning workflow. 
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2.1.4 Plan Evaluation 
A post planning comparison was performed to assess the congruence between the 
photon and proton plans. The following dose metrics were determined for each plan for 
the purposes of comparing the plans. 
1. Mean, maximum and minimum doses to the PTV. 
2. Dose to 95% of the PTV (D95) 
3. Conformity index 
4. Dose homogeneity index 
5. Mean and maximum doses to the brain 
6. Volume of brain receiving 5, 10, 50, 52 and 56 Gy-RBE Dose 
The minimum and maximum doses to the PTV were reported by the Eclipse 
treatment planning system.  These doses are point dose approximations and are 
equivalent to the D100% for Dmin and D0% for Dmax. 
The Mean dose and standard deviation of the mean was calculate using equations 
(6) and (7)  𝐷!"#$ = 𝐷!× !!!!        (6) 𝐷!" = 𝐷! − 𝐷!"#$ !× !!!      (7) 
where the mean dose Dmean is the sum of the the incremental dose from each dose 
bin Di multiplied by the volume from that bin vi divided by the total volume of the 
structure V. The incremental dose Di and volume vi were taken from the differential dose 
volume histogram (DVH). The dose exported with the differential DVH were separated 
by 0.1 Gy increments. This is equivalent to the mean dose given by the treatment 
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planning system and was found by Yoon et al. (2007) to be a more accurate measure of 
the homogeneity of the planned treatment volume. 
Conformity of the dose in the PTV is evaluated using the conformity index (CI) or 
conformity number as described by Feuvret et al. (2006). This metric is a measure of how 
well the dose conforms to the PTV contour and is  𝐶𝐼 = !"!"!" × !"!"!!"        (8) 
where TV is the target volume (PTV), TVRI is the target volume that is covered by the 
reference isodose, and VRI is the volume of the reference isodose. In this work the 
reference isodose was 95% (51.3 Gy-RBE) of the prescription dose. Conformity index 
has a range from 0 to 1, where 1 is ideal. The Dose to 95% was also used to quantify the 
coverage of the PTV and can be extracted from the cumulative DVH in tabular form. 
The dose homogeneity index is a measure of how homogeneous the dose is within 
the PTV.  This metrics was described by Yoon et al. (2007) and is given by  𝐻𝐼 = !!%!!!"%!!        (9) 
where D2% is the dose to 2% of the PTV volume, D98% is the dose to 98% of the PTV 
volume, and Dp is the prescribed dose. Homogeneity index has an optimal value of 0. 
2.2 Aim 2 – Risk Evaluation 
Plans were evaluated on radiation induced necrosis necrosis in the brain. The 
normal tissue complication probability (NTCP) was calculated for the whole brain using 
the Lyman Kutcher Burman (LKB) probit model (Burman, 1991). This model uses 4 
parameters and is given by 𝑁𝑇𝐶𝑃 = !!! 𝑒!!! !!!! 𝑑𝑡        (10) 𝑡 = !!"#!!"!" !!∙!"!" !       (11) 
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𝑇𝐷!" 𝜈 = !"!"!!""!       (12) 
where TD50 is the whole organ dose that would lead to 50% complication rate, m is the 
slope in the linear region of the sigmoidal dose response curve, n is a volume effect 
parameter and veff is the effective volume of the brain irradiated given by  
𝜈!"" = 𝜈! !!!!"# ! !!     (13) 
where vi is the fractional volume of sub volume i, di is the dose to sub volume i, and Dmax 
is the maximum dose to the volume of interest (VOI) (Kutcher and Burman, 1989). The 
other parameters used for equations 10-12 can be found in Table 2.4 
 
Table 2.4 Parameter used in brain necrosis NTCP calculation (Burman, 1991). 
Parameter Value Description 
m 0.15 Slope parameter 
n 0.25 Volume-effect parameter 
TD50 60 Gy 
Whole brain dose for an expected 
50% complication at 5yrs 
 
NTCP was evaluated for pairs of plans using the ratio of NTCP (rNTCP) given by 𝑟𝑁𝑇𝐶𝑃 = !"#$!"#$#%!"#$!"#$       (14) 
where the NTCP calculated for protons plans was divided by the NTCP calculated for the 
VMAT plans. 
2.3 Aim 3 – Sensitivity Analysis 
Calculation of the uncertainty in risk evaluation is a critical component in 
determining whether the results are accurate. Many uncertainties are dependent on 
planning uncertainty as well as effective delivery of the treatment plan. Setup uncertainty 
is a large portion of the uncertainty in effective delivery of which both protons and 
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photons are susceptible. Additionally, proton plans are susceptible to range uncertainties 
from planning to delivery.  Both setup uncertainty and range uncertainty was evaluated to 
determine the effect they have on the risk of necrosis using NTCP for 2 patients, 1 glioma 
(patient 5) and 1ependymoma (patient 12)  
Other sources of uncertainty may include the risk model itself.  For this reason 
other models were evaluated to determine the sensitivity of the ratio of risk between 
protons and photons based on the choice of models used.  
2.3.1 Setup Uncertainty 
 
To determine the NTCP dependence on proper plan delivery a maximum setup error 
of +1 cm in each dimension was simulated in the treatment planning system by moving 
the isocenter in each dimension individually to account for setup error at the time of 
treatment and patient movement. A common coordinate system was defined for both 
treatment planning system to ensure that the same shifts were made across systems. The 
common coordinate system can be seen in Table 2.5. Isocenter shifts were performed in 
Pinnacle v9.0 for VMAT plans and in Eclipse v11.0 for proton plans. For all sets of shifts 
it was important that only the dose was recalculated without changes in original plan 
optimization.  For VMAT plans this entailed copying the original plan and after shifting 
each point individually by 1 cm recalculating the dose for each beam in the beam 
spreadsheet based on the original beam weightings with no other modifications. For 
proton plans the dose was recalculated after shifts without recalculating the original 
beamline for IMPT plans and the beamline and compensator for passive scatter protons. 
The differential DVH for each of these shifts was exported for NTCP calculation and 
compared to the nominal plan. 
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Table 2.5 The commom coordinate system for isocenter shifts between treatment 
planning systems. Shifts in the x direction indicate lateral shifts, y direction indicate 
anterior-posterior shifts and z direct indicate superior inferior shift. The isocenter shift is 
opposite the table shift.  
Coordinate Table shift Isocenter shift 
+x patients right patients left 
-x patients left patients right 
+y anterior posterior 
-y posterior anterior 
+z inferior superior 
-z superior inferior 
 
2.3.2 Range Uncertainty 
 
Proton range uncertainty is largely caused by the conversion from Hounsfield units 
(HU) to relative linear proton stopping powers (Schaffner and Pedroni, 1998). HU’s are 
determined at the time of imaging and are a measure of the linear attenuation of the 
material compared to water (Bushberg, 2002). Eclipse v11.0 has tools to evaluate the 
effect of changes in the ratio of HU to stopping power conversions known as calibration 
curve errors.  Using this tool a +10% calibration curve error was simulated for the 2 
patients.  
The DVH’s for simulated calibration curve errors cannot be exported in tabular 
format from the Eclipse treatment planning system.  For this reason screen grabs were 
utilized in a program called plot digitizer v2.6.6.  These screen shots were then digitized 
as accurately as possible. NTCP was then calculated for digitized +10% calibration curve 
error and compared to the NTCP obtained using the nominal DVH curve. The ratio of 
NTCP from the calibration curve errors was then determined using equation 14. 
2.3.3 Risk Model Uncertainty 
 
Normal tissue complication probability is a widely used model for describing 
several secondary effects in many organs.  However, because of the inherent uncertainty 
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in predicting the risk of radiation necrosis, which is poorly understood, another 
uncertainty analysis was carried out. Alternative models were studied to determine if the 
relative predicted risk of necrosis is dependent on the choice of the model used to predict 
it. These models include several that have been widely used in second cancer prediction, 
such as the linear no-threshold model (LNT), linear threshold model (LT), linear plateau 
model (LP) and linear quadratic model (LQ), but that have not been applied to radiation 
necrosis. 
All models were fit to the total whole brain dose of 60 Gy to induce 50% 
complication (TD50) fromBurman (1991).  Additionally the linear threshold model 
passed through both the TD50 and TD5 points, which are 60 Gy and 45 Gy, respectively. 
The linear plateau model was fit to TD50 at 98% of the plateau max. Equations 15-18 
show the equations used for the initial fit  
LNT    𝑃 = 𝐷 ∙𝑚     (15) 
LT    𝑃 = 𝐷 ∙𝑚 − 𝑏    (16) 
LP    𝑃 = !! !!!! ∙ 1− 𝑒!!!!!    (17) 
LQ    𝑃 = 𝛼𝐷 − 𝛽𝐷!     (18) 
where P is the probability of complication, D is the dose, m is  a slope parameter, R is a 
risk parameter, 𝛼! is a linear plateau fit parameter, 𝛼 and β and the linear and quadratic 
fit parameters, respectively, for the linear quadratic equation. Table 2.6 shows the values 
of these fit parameters and the initial fit can be seen in Figure 2.7  
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Table 2.6 Alternative risk model fit parameters determined in this research. 
  m b R 𝛼! 𝛼 β 
LNT 0.00833333 - - - - - 
LT 0.03 1.3 - - - - 
LP - - 0.03325 0.0652 - - 
LQ - - - - 10.2 60 
 
 
 
Figure 2.7. Alternative risk models used to test the sensitivity of rNTCP to the shape of 
the model used. LNT is the linear no-threshold model, LT is the linear threshold model, 
LP(60) is the linear plateau model fit to 60 Gy at 98% of the maximum, and LQ is the 
linear quadratic model. 
 
TD5 and TD50 from Burman (1991) are based on the whole brain dose and since 
the current technique in this study only irradiates a fraction of the brain, the fractional 
volume for each 0.1 Gy dose bin was determined by dividing the volume irradiated in 
each dose bin as determined by the differential DVH by the total volume of the brain. 
This can be seen in the following equations 
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LNT    𝑅𝑖𝑠𝑘 = !!!!! ∙ 𝐷! ∙𝑚    (19) 
LT    𝑅𝑖𝑠𝑘 = !!!!! ∙ 𝐷! ∙𝑚 − 𝑏   (20) 
LP    𝑅𝑖𝑠𝑘 = !!!!! ∙ !! !!!! ∙ 1− 𝑒!!!!!   (21) 
LQ    𝑅𝑖𝑠𝑘 = !!!!! ∙ (𝛼𝐷! − 𝛽𝐷!!)   (22) 
where the fractional bin volumes were multiplied by the probability of risk for each dose 
bin and then summed over all bins. This has been done similarly by Rechner et al. (2012) 
to determine the overall risk. 
The ratio of risk between protons to photons will be determined using the 
following equation 𝑟𝑅𝑖𝑠𝑘 = !"#$!"#$#%!"#$!"#$      (23) 
where the risk from protons was divided by the risk from VMAT. The results were then 
compared to the baseline ratio of risk calculated from the LKB model.  
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Chapter 3 : Results 
Glioma and ependymoma plans had differences in treatment locations and 
coverage criteria.  Therefore a single patient from each group was selected for complete 
evaluation of isodose distribution and DVH comparison. Other metrics will be evaluated 
across all patients. Results will be presented for patients 5 and 12 first and then a 
comprehensive assessment will be made across other patients for the dosimetric and 
radiobiological results for the PTV and brain.  
  Isodose distributions for patients 5 and 12 are presented for a single transverse 
CT slice through plan isocenter.  In all images the PTV is shown in red color wash and 
isodose lines representing certain percentage dose levels are presented following the 
color coding system in Table 3.1. 
 
Table 3.1 Isodose and region of interest (ROI) display color scheme for isodose figures. 
Isodose or ROI Color 
59.4 Gy-RBE Yellow 
56.7 Gy-RBE Green 
54 Gy-RBE Blue 
51.3 Gy-RBE Cyan 
48.6 Gy-RBE Orange 
30-Gy-RBE Forest Green 
20 Gy-RBE Purple 
10 Gy-RBE Pink 
5 Gy-RBE Red 
PTV Red (color wash) 
Brain Magenta 
Brain Stem Green (color wash) 
Optic Chiasm Cyan (color wash) 
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DVH figures for selected patients 5 and 12 are shown in this section. All other 
patient DVH data are presented in Appendix B: Patient DVH.  All DVH figures include 
PTV, brain, brainstem, and optic chiasm for VMAT, passively scattered proton therapy 
(PSPT), and IMPT plans. The color-coding for all DVH ROIs is listed in Table 3.1. 
3.1 Patient 5 
Patient 5 was a 9-year-old female with a glioma designated in the right cerebral 
hemisphere. In patient 5, as in all other patients, the tumor was considered totally 
resected or sub-totally resected before the radiation therapy.  
3.1.1 Isodose distribution comparison 
Isodose distributions for VMAT, PSPT, and IMPT plans are plotted in Figure 
3.1(a-c).  All plans are shown for a transverse CT slice at plan isocenter indicated by the 
yellow line in Figure 3.1(d).  
All plans have a max dose less than 105% of the prescription dose (56.7 Gy-RBE) 
to the PTV. In the selected slice the coverage for the VMAT plan looks considerably 
worse. Complete coverage of the PTV is to the 90% (48.6 Gy-RBE) isodose line 
compared to the 95% (51.3 Gy-RBE) for PSPT and IMPT plans.  The homogeneity of the 
proton plans at the 100% (54 Gy-RBE) isodose line appear to be worse than the VMAT 
plan.  
The low dose region is largely different between the VMAT and proton plans. 
The 5-30 Gy-RBE isodose lines encompass a much larger volume of normal tissue in the 
VMAT plans as compared to both proton plans.  The IMPT plan shown in Figure 3.1c 
has a greater extension of the 5-20 Gy-RBE isodose lines into the normal brain tissue  
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Figure 3.1. Patient 5 isodose distribution at isocenter CT slice location for (a) VMAT, (b) 
PSPT, and (c) IMPT. Axial CT slice location (d) is represented by the yellow line. 
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compared to the PSPT plan shown in Figure 3.1b.  This is due to the increase in photon 
exit dose for VMAT plans and the number of beams used to create the IMPT plans, 
respectively.  The IMPT plan for patient 5 was constructed in a 3-beam arrangement and 
the dose extension into the normal brain tissue is along those beam angles.  
3.1.2 DVH Comparison 
Figure 3.2 plots the DVH for VMAT, PSPT, and IMPT plans for patient 5.  The 
shoulder of the PTV is typically used to determine plan coverage.  This is the region 
where the PTV DVH curve drops away from the 100% line.  For patient 5 the IMPT plan 
has the greatest coverage with the narrowest shoulder and steeper fall off than the other 2 
plans. The PTV for the PSPT plan has the worst coverage.  The DVH line drops away 
from the 100% early and has a slow gradual reduction in the volume covered up to the 
prescription dose where it falls sharply.  The VMAT plan also drops away from the 100% 
volume line relatively early and falls off much less sharply at the prescription. 
 
Figure 3.2. The dose volume histograms (DVH) for patient 5. VMAT plans are 
represented with the solid lines, PSPT with the dotted lines and IMPT with the dash-dot 
lines. Different regions of interest are represented with different colored lines. 
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Compared to VMAT, proton therapy consistently reduced the dose to organs at 
risk. This trend can also be seen in Figure 3.2 for patient 5. For the brainstem, IMPT and 
PSPT plans have a high dose tail compared to VMAT.  Similar results are seen with the 
optic chiasm between plans.  
3.1.3 PTV 
PTV results for patient 5 are shown in Table 3.2. This patient had a glioma that 
was situated low in cerebral hemisphere with brainstem involvement. In almost every 
dose metric the IMPT plan showed better results. The reduction in the PTV mean and 
minimum dose for the VMAT and PSPT is likely due to the dose constraints place on the 
brainstem and as a result the dose to the PTV was sacrificed.  This can be seen in the 
failure of the VMAT and PSPT plans to reach the planning objective of D95%= 51.3 Gy-
RBE or 95% of the prescription dose. For this reason the conformity and homogeneity of 
both the VMAT and PS proton plans also suffered but were similar to each other. 
Table 3.2 The mean, maximum, minimum conformity index (CI), homogeneity index 
(HI) and dose to 95% (D95%) of the PTV for patient 5. 
Treatment 
Plans 
Dmean  
(Gy-RBE) 
Dmax  
(Gy-RBE) 
Dmin  
(Gy-RBE)  
D95%  
(Gy-RBE) CI HI 
VMAT 52.5 57.5 31.7 48.8 0.60 0.21 
PSPT 52.9 63.2 0.5 49.5 0.57 0.46 
IMPT 54.1 57.2 39.2 52.8 0.84 0.07 
 
3.1.4 Brain 
Dosimetric results for patient 5 brain ROI are shown in Table 3.3 and Table 3.4. 
Compared to the VMAT plan, the PSPT plan resulted an increase in the maximum dose 
and a decrease in the mean dose to the brain.  The IMPT plan also resulted in a reduction 
of the mean brain dose compared to the VMAT plan, with a maximum dose that was 
similar to the VMAT plan.  
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Table 3.3 The mean and maximum doses to the brain for patient 5. 
Patient 5  
Dmax      
(Gy-RBE) 
Dmean      
(Gy-RBE) 
VMAT 57.5 23.2 
PSPT 63.2 10.0 
IMPT 58.0 15.0 
 
The PSPT plan shows smaller volume receiving low dose compared to VMAT or 
IMPT plan, as seen by the V5Gy-RBE and V10Gy-RBE of 22% and 21%, respectively (Table 
3.4). The volume receiving high dose was similar across VMAT, PSPT, and IMPT plans 
and the calculated NTCP was similar with values of 0.14%, 0.10%, and 0.08% risk of 
radiation necrosis for VMAT, PSPT and IMPT, respectively.   
Table 3.4 The volume of the brain receiving 5, 10 50, 52, and 56 Gy-RBE and normal 
tissue complication probability (NTCP) of brain necrosis for patient 5. 
Treatment 
plans 
V5Gy-RBE 
(%) 
V10Gy-RBE 
(%) 
V50Gy-RBE 
(%) 
V52Gy-RBE 
(%) 
V56Gy-RBE 
(%) NTCP(%) 
VMAT 82.2 73.7 13.1 8.6 0.2 0.14 
PSPT 22.4 21.0 14.1 13.0 0.3 0.10 
IMPT 53.3 47.5 12.0 10.8 0.0 0.08 
 
3.2 Patient 12 
Patient 12 was a 16-year-old female with an ependymoma designated 
infratentorial in the posterior fossa which can be seen in Figure 3.3.  All ependymomas 
were considered sub-totally resected which generally calls for radiation therapy 
treatment.  
3.2.1 Isodose distribution comparison 
Figure 3.3 displays the isodose lines for patient 12 taken from a CT through the 
plan isocenter. The location of the CT slice within the patient can be seen by the yellow 
line in Figure 3.3(d).  
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Figure 3.3. Patient 12 isodose distributions for VMAT (a), PSPT (b) and IMPT (c). CT 
slice location is through isocenter and is designated by a yellow line in figure d. 
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The VMAT plan (Figure 3.3(a)) shows fairly good coverage to the 95% (51.3 Gy-
RBE) isodose line, which covers all but small region of the PTV anteriorly. However the 
VMAT plan shows little coverage to the 100% (54 Gy-RBE) isodose line. The PSPT plan 
had good homogeneity to the 95% (51.3 Gy-RBE) isodose line with only incomplete 
coverage where distal blocking is used. However the coverage 100% (54 Gy-RBE) was 
poor. The IMPT plan had similarities to the PSPT and VMAT plans. Coverage of the 
100% (54 Gy-RBE) isodose line is was poor but there is excellent coverage with the 95% 
(51.3 Gy-RBE) line. 
The VMAT plan resulted in an greater extension of the low dose region into the 
normal brain tissue compared to either proton plans with the 5-30 Gy isodose lines 
extending much further from the PTV. The PSPT plan resulted in much less low dose 
region to the brain than either VMAT or IMPT, likely due to fewer number of beams and 
beam angle selection. The IMPT plan resulted in a greater extension of the 5-30 Gy-RBE 
isodose lines into surrounding brain tissue than the PSPT but a reduction compared to the 
VMAT plan.  
3.2.2 DVH comparison 
Comparison of the DVH between the plans for patient 12 can be seen in Figure 
3.4.  The PTV for the VMAT and IMPT plans are very similar with only a slightly 
broader shoulder for the IMPT plan and a slightly larger volume receiving a higher dose 
as seen in the tail of the PTV curve.  The PSPT (dotted line) curves has a much larger 
shoulder that dips away from the 100% volume at around 10 Gy-RBE and slowly falls 
until it drops sharply just before the prescription dose of 54 Gy-RBE.  This characteristic 
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is due in part to the overlap of the PTV with the brainstem and the use of distal blocking 
to reduce the dose to the brainstem to the level of the constraint that was set upon it.  
 
Figure 3.4. The dose volume histogram (DVH) for patient 12. VMAT plans are 
represented with the solid lines, PSPT with the dotted lines and IMPT with the dash-dot 
lines. Different regions of interest are represented with different colored lines. 
 
 
Both proton plans showed a reduction in the volume of the brainstem receiving 
dose compared to VMAT, except in the high dose region for the PSPT plan.  The PSPT 
plan shows a reduction in the total brain dose compared to VMAT, but VMAT and IMPT 
plans were very similar.  Both proton plans also resulted in much lower dose to the optic 
chiasm compared to VMAT. 
3.2.3 PTV  
The PTV dose metrics for patient 12 are listed in Table 3.5. The mean dose for all 
plans was very similar with an average of 53.2 + 0.4 Gy-RBE for all plans. However the 
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minimum dose for the proton plans was much lower which is revealed by an inferior 
homogeneity index than that for the VMAT plan. Additionally the D95% for the PSPT 
plan fell below 90% (48.6 Gy-RBE) of the prescription dose, which was our criterion for 
acceptance of our ependymoma plans.  Again, this is due to the overlap of the PTV with 
the brainstem and the constraint that was placed on the brainstem. Conformity index of 
the PTV was highest for IMPT (0.76), intermediated for VMAT plans (0.63), and lowest 
for PSPT (0.49). 
Table 3.5 The mean, maximum, minimum conformity index (CI), homogeneity index(HI) 
and dose to 95% (D95%) of the PTV for patient 12. 
Treatment 
Plans 
Dmean  
(Gy-RBE) 
Dmax  
(Gy-RBE) 
Dmin  
(Gy-RBE)  
D95%  
(Gy-RBE) CI HI 
VMAT 53.3 54.7 42.8 50.6 0.63 0.09 
PSPT 52.7 60.0 3.5 46.5 0.49 0.39 
IMPT 53.5 58.2 32.8 50.2 0.76 0.14 
 
3.2.4 Brain 
Table 3.6 and 3.7 list the predicted dosimetric and radiobiological results in the 
brain for patient 12. The maximum dose to the brain for patient 12 was higher for both 
the PSPT and IMPT compared to the VMAT plan.  Additionally the mean doses for both 
the PSPT and IMPT plans were slightly lower than that for the VMAT plan.  
 
Table 3.6 The mean and maximum doses to the brain for patient 12. 
Patient 12 
Dmax    
(Gy-RBE) 
Dmean        
(Gy-RBE) 
VMAT 54.7 11.1 
PSPT 60.3 6.2 
IMPT 60.9 9.9 
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Table 3.7 The volume of the brain receiving 5, 10 50, 52, and 56 Gy-RBE and normal 
tissue complication probability (NTCP) for patient 12. 
Treatment 
Plans 
V5Gy-RBE 
(%) 
V10Gy-RBE 
(%) 
V50Gy-RBE 
(%) 
V52Gy-RBE 
(%) 
V56Gy-RBE 
(%) NTCP(%) 
VMAT 31.2 27.9 8.0 6.4 0.0 0.027 
PSPT 14.2 13.3 8.3 7.1 0.3 0.022 
IMPT 33.4 29.4 6.4 5.6 0.0 0.015 
 
The volume of the brain irradiated between 5 and 56 Gy-RBE is relatively similar 
between VMAT and IMPT as seen in Table 3.7. The volume of brain irradiated to 5 and 
10 Gy-RBE for the PSPT plan was less than half the value of the VMAT plan, however 
the PSPT plan had a similar volume irradiated at the higher dose point between 50-56 
Gy-RBE as the VMAT and IMPT plans. Again the NTCP values were similar between 
plans with a slight reduction for the IMPT plan compared to the VMAT plan. 
3.3 Overview of all patients 
Results for all patients are presented in the following section. All metrics were 
compared for significance using the Student’s t-test and Wilcoxon signed rank test 
(WSR). 
3.3.1 PTV 
Table 3.8 lists the mean, maximum and minimum doses to the PTV for the entire 
pediatric cohort (patients 1-13).  The average mean dose to the PTV was 53.8 + 0.6 Gy-
RBE for both VMAT and IMPT plans and showed no significant difference for either the 
Student’s t-test or the Wilcoxon signed rank test, but the PSPT plans had a significantly 
lower mean dose to the PTV (53.3 + 0.6 Gy-RBE) than VMAT or IMPT plans. The 
maximum dose to the PTV for all patients is displayed in Figure 3.5 and was significantly 
different from VMAT for both IMPT and PSPT. Both PSPT and IMPT resulted in a 
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higher average maximum dose, with values of 58.3 + 2.5 and 57.4 + 1.0 Gy-RBE, 
respectively, compared to VMAT which had an average maximum dose of 55.8 + 1.0 
Gy-RBE. The minimum dose to the PTV was significantly lower for PSPT and IMPT 
plans with average minimum values of 23.0 + 21.1, 36.5 + 10.4, respectively, compared 
to VMAT which had an average minimum dose of 45.3 + 5.5 Gy-RBE. 
Table 3.8 The mean, maximum and minimum dose to the PTV for all patients. 
Descriptive statistics include the mean value with standard deviation (SD), and the p-
value for the student t-test and Wilcoxon signed rank (WSR) test. 
Patient 
index 
Dmean (Gy-RBE) Dmax (Gy-RBE) Dmin (Gy-RBE)  
VMAT PSPT IMPT VMAT PSPT IMPT VMAT PSPT IMPT 
1 54.2 53.9 54.2 55.3 57.5 55.8 50.9 47.2 47.4 
2 54.0 53.9 53.9 55.0 57.8 58.9 51.5 48.3 46.1 
3 54.5 53.1 53.5 56.2 57.6 58.5 46.4 30.9 35.1 
4 54.2 53.8 54.0 57.7 59.6 56.8 39.7 22.5 33.9 
5 52.5 52.9 54.1 57.5 63.2 57.2 31.7 0.5 39.2 
6 54.0 53.7 54.2 55.3 55.8 56.3 52.2 45.3 47.2 
7 54.2 53.9 54.1 55.5 55.6 56.6 48.8 46.3 43.7 
8 53.9 53.7 54.3 56.0 56.4 58.7 46.7 43.9 45.7 
9 53.3 53.1 53.8 55.2 57.4 57.8 44.8 1.0 36.3 
10 54.5 52.1 52.0 57.0 56.8 57.4 44.1 7.6 11.1 
11 53.7 53.3 53.8 54.6 57.6 58.3 44.1 1.4 29.5 
12 53.3 52.7 53.5 54.7 60.0 58.2 42.8 3.5 32.8 
13 53.6 52.8 53.6 55.5 63.1 56.2 44.7 0.5 25.8 
Mean 53.8 53.3 53.8 55.8 58.3 57.4 45.3 23.0 36.5 
SD 0.6 0.6 0.6 1.0 2.5 1.0 5.5 21.1 10.4 
p-
value - 
VMAT-
PSPT 
VMAT-
IMPT - 
VMAT-
PSPT 
VMAT-
IMPT - 
VMAT-
PSPT 
VMAT-
IMPT 
t-test - 0.02 0.8 - 0.003 0.003 - 0.0007 0.007 
WSR - 0.01 0.8 - 0.002 0.005 - 0.002 0.008 
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Figure 3.5 The maximum dose to the PTV for all patients and treatment plans. 
 
Table 3.9 summarizes the results for the conformity index (CI), homogeneity 
index (HI) and dose to 95% of the PTV (D95%) and these results are also displayed in 
Figure 3.6 through 3.8 for all patients.  PSPT plans showed no significant difference in 
the conformity compared to VMAT with average CI values of 0.58 + 0.07 and 0.62 + 
0.08, respectively. The IMPT plans resulted in significantly better conformity than the 
VMAT plans with an average CI value of 0.83 + 0.06 versus 0.62 + 0.08 for VMAT.   
The homogeneity of the dose to the PTV was determined with the homogeneity 
index. With an optimal value of zero both the VMAT and IMPT plans showed good 
homogeneity with average HI values of 0.07 + 0.05 and 0.12 + 0.12. On the other hand, 
PSPT plans had significantly worse homogeneity than the VMAT plans with an average 
HI of 0.23 + 0.19.  
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The dose to 95% of the volume (D95%) was also used as an indicator of PTV dose 
coverage. PSPT plans resulted in a significantly lower average D95% than the VMAT 
plans and 5 of the 13 plans did not meet the criteria for acceptable coverage. IMPT and 
VMAT average D95% values were not significantly different from one another and only 
one patient from each modality failed to meet the coverage criteria (patient 10 and 5, 
respectively).  
Table 3.9 Conformity index (CI), homogeneity index (HI), and dose to 95% of the PTV 
(D95%) for all patients. Descriptive statistics include the mean value with standard 
deviation (SD), and the p-value for the student t-test and Wilcoxon signed rank (WSR) 
test. 
Patient 
index 
CI HI D95% (Gy-RBE) 
VMAT PSPT IMPT VMAT PSPT IMPT VMAT PSPT IMPT 
1 0.57 0.59 0.84 0.02 0.08 0.05 53.8 52.3 53.1 
2 0.68 0.59 0.86 0.02 0.05 0.07 53.4 52.8 52.9 
3 0.74 0.63 0.77 0.06 0.16 0.08 53.2 49.4 52.1 
4 0.64 0.60 0.88 0.11 0.11 0.08 52.5 51.9 52.6 
5 0.60 0.57 0.84 0.21 0.46 0.07 48.8 49.5 52.8 
6 0.55 0.61 0.87 0.03 0.06 0.05 53.5 52.6 53.2 
7 0.62 0.62 0.89 0.02 0.06 0.07 53.7 52.6 52.6 
8 0.73 0.67 0.92 0.03 0.06 0.05 53.3 52.8 53.2 
9 0.62 0.49 0.83 0.10 0.29 0.12 50.6 50.6 51.1 
10 0.44 0.63 0.73 0.11 0.40 0.50 52.5 43.9 40.7 
11 0.60 0.58 0.84 0.05 0.28 0.15 52.8 50.8 51.4 
12 0.63 0.49 0.76 0.09 0.39 0.14 50.6 46.5 50.2 
13 0.64 0.43 0.80 0.08 0.61 0.16 51.8 47.5 50.9 
Mean 0.62 0.58 0.83 0.07 0.23 0.12 52.35 50.25 51.29 
SD 0.08 0.07 0.06 0.05 0.19 0.12 1.50 2.82 3.33 
p-value - 
VMAT-
PSPT 
VMAT-
IMPT - 
VMAT-
PSPT 
VMAT-
IMPT - 
VMAT-
PSPT 
VMAT-
IMPT 
t-test - 0.2 0.0000004 - 0.003 0.1 - 0.01 0.3 
WSR - 0.1 0.002 - 0.002 0.08 - 0.005 0.07 
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Figure 3.6 The conformity of the dose to the PTV represented by the conformity index 
for VMAT, PSPT, and IMPT for all patients. 
 
Figure 3.7 The homogeneity of the dose to the PTV represented by the homogeneity 
index for VMAT, PSPT, and IMPT for all patients. 
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Figure 3.8 The dose to 95% of the PTV (D95%) for VMAT, PSPT, and IMPT for all 
patients. 
 
3.3.2 Brain 
Table 3.10 lists the mean and max doses to the brain for all patients. The 
maximum dose to the brain for all patients is displayed in Figure 3.9. Both IMPT and 
PSPT plans resulted in a significantly higher maximum dose to the brain than the VMAT 
plans with average maximum values of 57.6 + 1.44, 58.5 + 2.51, and 55.8 + 1.08 Gy-
RBE, respectively. The mean dose to the brain was significantly lower for both the PSPT 
and IMPT plans compared to VMAT with average mean values of 7.9 + 1.1, 10.3 + 4.0, 
and 17.5 + 5.6 Gy-RBE, respectively. 
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Table 3.10 The maximum and mean doses to the brain for all patients. Descriptive 
statistics include the mean value with standard deviation (SD), and the p-value for the 
student t-test and Wilcoxon signed rank (WSR) test. 
Patient 
index 
Dmax (Gy-RBE) Dmean (Gy-RBE) 
VMAT PSPT IMPT VMAT PSPT IMPT 
1 55.3 57.9 55.8 21.2 9.3 12.9 
2 55.0 57.8 58.9 17.2 6.3 8.1 
3 56.2 57.6 58.5 9.4 4.9 5.7 
4 58.0 60.2 56.8 27.4 12.9 16.5 
5 57.5 63.2 58.0 23.2 10.0 15.0 
6 55.4 55.8 55.8 17.7 5.4 5.4 
7 55.5 55.6 56.6 14.3 4.7 6.9 
8 55.3 56.6 58.7 24.3 12.1 16.2 
9 55.2 57.5 57.5 11.0 6.2 6.3 
10 57.0 56.8 57.4 13.8 6.2 8.5 
11 54.6 57.6 58.3 16.2 7.7 9.3 
12 54.7 60.3 60.9 11.1 6.2 9.9 
13 55.5 63.2 56.3 20.5 10.9 12.8 
Average 55.8 58.5 57.6 17.5 7.9 10.3 
SD 1.08 2.51 1.44 5.59 2.80 3.99 
p-value - 
VMAT-
PSPT 
VMAT-
IMPT - 
VMAT-
PSPT 
VMAT-
IMPT 
t-test - 0.002 0.01 - 0.0000003 0.000001 
WSR - 0.005 0.007 - 0.001 0.001 
 
 
Figure 3.9 The maximum dose to the brain for VMAT, PSPT, and IMPT for all patients. 
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The percentage volume of the brain receiving 5, 10, 50, 52, and 56 Gy-RBE is 
listed in Table 3.11 and 3.12.  These result show that both the PSPT and IMPT plans 
resulted in a significant reduction in the volume of the brain that was irradiated to the 5 
and 10 Gy-RBE dose levels compared to VMAT. VMAT plans resulted in a low dose 
bath of 10 Gy-RBE to nearly 50% of the brain. PSPT and IMPT reduced the volume 
receiving 10 Gy-RBE to nearly half of that from VMAT. Additionally, the IMPT plans 
resulted in a reduction of the brain volume receiving 50 Gy-RBE compared to VMAT.  
There was no statistically significant difference between any of the plans at the 52 and 56 
Gy-RBE dose based on the Wilcoxon signed rank test. 
Table 3.11 The percentage volume of the brain receiving 5 and 10 Gy-RBE for all 
patients. Descriptive statistics include the mean value with standard deviation (SD), and 
the p-value for the student t-test and Wilcoxon signed rank (WSR) test. 
Patient 
index 
V5Gy-RBE (%) V10Gy-RBE (%) 
VMAT PSPT IMPT VMAT PSPT IMPT 
1 72.7 22.0 47.3 51.4 20.2 41.1 
2 69.3 14.4 26.1 54.0 13.5 23.1 
3 40.8 17.0 25.7 29.5 15.5 20.7 
4 85.8 29.0 56.8 78.3 27.2 50.6 
5 82.2 22.4 53.3 73.7 21.0 47.5 
6 62.7 12.5 35.6 45.4 11.6 30.2 
7 60.9 11.0 22.9 47.1 10.2 20.3 
8 84.0 26.8 54.2 62.4 25.3 49.2 
9 31.6 14.3 19.2 28.3 13.4 17.1 
10 40.4 18.1 34.0 34.2 16.7 28.9 
11 49.6 17.6 28.2 40.6 16.4 25.0 
12 31.2 14.2 33.4 27.9 13.3 29.4 
13 65.0 25.4 49.7 56.6 23.7 43.1 
Average 59.71 18.84 37.41 48.42 17.54 32.78 
SD 19.40 5.79 13.16 16.57 5.46 11.96 
p-value   
VMAT-
PSPT 
VMAT-
IMPT   
VMAT-
PSPT 
VMAT-
IMPT 
t-test   0.000001 0.00004   0.000002 0.0001 
WSR   0.001  0.02    0.001  0.02 
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Table 3.12 The percentage volume of the brain receiving 50, 52, and 56 Gy-RBE for all 
patients. Descriptive statistics include the mean value with standard deviation (SD), and 
the p-value for the student t-test and Wilcoxon signed rank (WSR) test. 
Patient 
index 
V50Gy-RBE (%) V52Gy-RBE (%) V56Gy-RBE (%) 
VMAT PSPT IMPT 
VMA
T PSPT IMPT VMAT PSPT IMPT 
1 16.1 12.3 9.9 13.6 11.2 9.0 0.0 0.1 0.0 
2 9.3 9.0 7.0 8.0 8.3 6.3 0.0 0.0 0.1 
3 3.2 2.8 2.9 2.6 2.4 2.7 0.0 0.0 0.0 
4 19.6 18.4 13.9 16.6 17.0 12.6 0.4 0.1 0.0 
5 13.1 14.1 12.0 8.6 13.0 10.8 0.2 0.3 0.0 
6 9.7 7.6 5.7 8.1 6.9 5.1 0.0 0.0 0.0 
7 7.9 6.4 5.3 6.8 5.9 4.8 0.0 0.0 0.0 
8 19.7 17.9 15.2 17.2 16.9 14.1 0.0 0.0 0.0 
9 7.3 8.1 5.6 5.7 7.1 5.0 0.0 0.1 0.0 
10 10.5 5.6 5.3 8.9 4.8 4.4 0.4 0.0 0.0 
11 13.6 10.8 8.9 11.6 10.0 8.1 0.0 0.1 0.1 
12 8.0 8.3 6.4 6.4 7.1 5.6 0.0 0.3 0.0 
13 12.0 13.4 8.7 9.6 11.7 7.7 0.0 0.7 0.0 
Average 11.54 10.36 8.23 9.52 9.39 7.40 0.08 0.13 0.02 
SD 4.84 4.70 3.68 4.23 4.44 3.42 0.15 0.20 0.03 
p-value   
VMAT
-PSPT 
VMAT-
IMPT   
VMAT
-PSPT 
VMAT
-IMPT   
VMA
T-
PSPT 
VMAT
-IMPT 
t-test   0.05 0.00003   0.8 0.002   0.5 0.2 
WSR    0.6  0.001    0.8 0.08    0.4  0.01 
 
The calculated risk of necrosis and ratio of risk are summarized by the NTCP and 
rNTCP values seen in Table 3.13. Both PSPT and IMPT resulted in a significant 
reduction in the NTCP compared to VMAT with average values of 0.065 + 0.07 %, 0.042 
+ 0.05 %, and 0.074 + 0.05 %, respectively. This reduction can be seen in the ratio of 
normal tissue complication probability (rNTCP) with average values of 0.51 + 0.3 for 
PSPT compared to VMAT and 0.32 + 0.1 for IMPT compared to VMAT. The values of 
rNTCP for all PSPT and IMPT can be seen in Figure 3.10 and 3.11, respectively, for all 
patients compared to the average values. rNTCP values were compared to 1 using the 
 48 
Wilcoxon signed rank test and were found to be significantly lower than 1, indicating that 
both proton modalities should confer a reduction in the risk of necrosis. 
Table 3.13 The normal tissue complication probability (NTCP) and ratio of normal tissue 
complication probability between plans for all patients. Descriptive statistics include the 
mean value with standard deviation (SD), and the p-value for the student t-test and 
Wilcoxon signed rank (WSR) test. 
Patient 
index 
NTCP(%) rNTCP 
VMAT PSPT IMPT PSPT/VMAT IMPT/VMAT 
1 0.247 0.068 0.046 0.28 0.19 
2 0.045 0.025 0.016 0.55 0.36 
3 0.0035 0.0014 0.0014 0.39 0.39 
4 0.45 0.23 0.13 0.50 0.28 
5 0.1433 0.1031 0.0821 0.72 0.57 
6 0.0694 0.0150 0.0097 0.22 0.14 
7 0.0276 0.0095 0.0075 0.35 0.27 
8 0.38 0.19 0.15 0.49 0.41 
9 0.0230 0.0216 0.0090 0.94 0.39 
10 0.0736 0.0076 0.0078 0.10 0.11 
11 0.117 0.047 0.034 0.40 0.29 
12 0.027 0.022 0.015 0.80 0.54 
13 0.130 0.111 0.034 0.85 0.26 
Mean  0.074 0.065 0.042 0.51 0.32 
SD 0.05 0.07 0.05 0.3 0.1 
p-value   
VMAT-
PSPT VMAT-IMPT 
VMAT-
PSPT 
VMAT-
IMPT 
t-test   0.01 0.01     
WSR       0.002 0.002 
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Figure 3.10 The ratio of risk (rNTCP) for PSPT plans compared to VMAT for all patients 
and compared with the average value of rNTCP represented by the red circle with 
standard deviation error bars.  
 
Figure 3.11 The ratio of risk (rNTCP) for IMPT plans compared to VMAT for all patients 
and compared with the average value of rNTCP represented by the red circle with 
standard deviation error bars. 
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3.4 Sensitivity Analysis 
Isocenter shifts and range uncertainty estimates were calculated for patient 5 and 
12 to determine the effects of setup error and changes in the CT number, respectively. 
Risk model analysis was performed for the entire pediatric cohort (patients 1-13) to 
determine the sensitivity of predicted risk on the choice of risk model used. 
 
3.4.1 Isocenter shifts 
The dose volume histograms (DVHs) for patient 5 and 12 isocenter shifts are 
shown in Appendix C (Figure C.1 through C.18) for VMAT, PSPT and IMPT plans. 
Additionally the results are summarized in Table C.1 through Table C.18. For both 
patients 5 and 12 the mean and minimum dose to the PTV and the dose to 95% of the 
PTV decreased with most isocenter shifts. The maximum dose to the PTV changed little 
for any of the isocenter shifts compared to the nominal plan. In the brain there was also 
little change in the mean and maximum doses except in the case of IMPT plans. The 
maximum dose to the brain for IMPT showed an increase with most isocenter shifts and 
the increase was up to 10 Gy. The volumes of the brain receiving high and low doses 
(V5Gy, V10Gy, V50Gy, V52Gy, and V56Gy) also changed little for most of the isocenter shifts 
compared to the nominal plan.   
The small changes in the brain irradiation resulted in minor variations in NTCP 
and rNTCP. rNTCP results for patients 5 and 12 are summarized in Table 3.14 and 3.15 
and displayed in Figure 3.12 and 3.13, respectively. From the figures it is clear that there 
is little change in rNTCP for either patient with isocenter shifts compared to the nominal 
plan. For patient 5 the greatest change in rNTCP was 0.12 from a right lateral shift (x-1 
cm) in the PSPT plan and 0.18 from a superior shift (z+1 cm) in the IMPT plan. The 
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greatest changes in rNTCP for patient 12 for PSPT and IMPT plans resulted from a 
superior shift (z+1 cm) and left lateral shift (z+1 cm) and were 0.11 and 0.08, 
respectively. 
 
Table 3.14 The ratio of normal tissue complication probability (rNTCP) for isocenter 
shifts in patient 5.  
rNTCP PSPT/VMAT IMPT/VMAT 
nominal 0.72 0.57 
x+1 (left lateral) 0.67 0.52 
x-1 (right lateral 0.84 0.51 
y+1 (posterior) 0.70 0.57 
y-1 (anterior) 0.79 0.55 
z+1 (superior 0.75 0.75 
z-1 (inferior) 0.69 0.47 
 
Table 3.15 The ratio of normal tissue complication probability (rNTCP) for isocenter 
shifts in patient 12. 
rNTCP PSPT/VMAT IMPT/VMAT 
nominal 0.80 0.54 
x+1 (left lateral) 0.76 0.46 
x-1 (right lateral 0.71 0.49 
y+1 (posterior) 0.73 0.55 
y-1 (anterior) 0.85 0.51 
z+1 (superior 0.91 0.61 
z-1 (inferior) 0.76 0.62 
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Figure 3.12 The change in rNTCP with isocenter shifts for patient 5. 
 
Figure 3.13 The change in rNTCP with isocenter shifts for patient 12. 
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3.4.2 Range Uncertainty Analysis 
PSPT and IMPT DVHs with CT calibration curve errors for patient 5 and 12 are 
shown in Figure 3.14 through 3.17. The changes in calibration curve affect the 
conversion of Hounsfield units to proton stopping powers, ultimately resulting in a 
change in proton range.  An increase of the calibration curve by 10% decreased proton 
range with a reduction of the doses for all structures compared to the nominal plan. A 
decrease in the calibration curve of 10% had the opposite effect with an increase in the 
proton range and increase of distal doses. The brain differential DVH curve was used for 
NTCP calculation. 
 
Figure 3.14 Screen shot of a plus and minus 10% calibration curve error for patient 5 
PSPT DVH curve.  Dotted lines represent the calibration error curve and the solid lines 
are the nominal plan curves. 
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Figure 3.15 Screen shot of a plus and minus 10% calibration curve error for patient 5 
IMPT DVH curve.  Dotted lines represent the calibration error curve and the solid lines 
are the nominal plan curves. 
 
Figure 3.16 Screen shot of a plus and minus 10% calibration curve error for patient 12 
PSPT DVH curve.  Dotted lines represent the calibration error curve and the solid lines 
are the nominal plan curves. 
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Figure 3.17 Screen shot of a plus and minus 10% calibration curve error for patient 12 
IMPT DVH curve.  Dotted lines represent the calibration error curve and the solid lines 
are the nominal plan curves. 
NTCP  and rNTCP results for patients 5 and 12 are summarized in Table 3.16 
through 3.19 and displayed in Figure 3.18 and Figure 3.19. In both patients an increase in 
the calibration curve by 10% resulted in a reduction of NTCP for both PSPT and IMPT 
plans. A reduction of the calibration curve by 10% has the opposite effect and increased 
NTCP to levels near those of the VMAT plans.  
 
Table 3.16 Effects of calibration curve error on NTCP for proton plans compared to the 
nominal in patient 5 
 
NTCPVMAT NTCPPSPT NTCPIMPT 
Nominal 0.14 0.10 0.08 
+10%  - 0.08 0.03 
-10%  - 0.14 0.12 
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Table 3.17 The ratio of NTCP (rNTCP) for calibration curve errors in patient 5. 
rNTCP PSPT/VMAT IMPT/VMAT 
Nominal 0.72 0.57 
10% 0.57 0.20 
-10% 0.99 0.84 
 
Table 3.18 Effects of calibration curve error on NTCP for proton plans compared to the 
nominal for all plans for patient 12 
 
NTCPVMAT NTCPPSPT NTCPIMPT 
Nominal 0.027 0.022 0.015 
10%  - 0.017 0.007 
-10%  - 0.026 0.023 
 
Table 3.19 Ratio of NTCP for calibration curve errors in patient 12. 
rNTCP PSPT/VMAT IMPT/VMAT 
Nominal 0.80 0.54 
10% 0.61 0.25 
-10% 0.95 0.84 
 
 
Figure 3.18 The ratio of normal tissue complication probability (rNTCP) for patient 5 
with +10% calibration curve errors compared to the nominal rNTCP. 
 57 
 
 
Figure 3.19 The ratio of normal tissue complication probability for patient 12 with +10% 
calibration curve errors compared to the nominal rNTCP. 
3.4.3 Risk Model Analysis 
Table 3.20 and 3.21 summarize the results of the predicted risk of necrosis at 5 
years post treatment calculated with the linear non threshold (LNT), linear threshold 
(LT), linear quadratic (LQ), and linear plateau (LP) models compared with the baseline 
risk calculated using the Lyman Kutcher Burman (LKB) model. All alternative risk 
models resulted in a higher percentage risk than the baseline LKB model. However, most 
of the models still showed a significant decrease in the risk for proton plans compared to 
VMAT plans. Only the linear threshold model for the PSPT plans resulted in risks that 
were not significantly different from the VMAT plans with an average value of 2.5 + 1.2 
% (PSPT) compared to 2.7 + 1.2 % (VMAT). 
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Table 3.20 Calculated risk of necrosis using the linear non threshold (LNT) model and 
linear threshold (LT) model compared to the baseline risk calculated with the Lyman 
Kutcher Burman model for all patients. Descriptive statistics include the mean value with 
standard deviation (SD), and the p-value for the student t-test and Wilcoxon signed rank 
(WSR) test. 
Patient 
index 
LNT(%) LT(%) Baseline LKB(%) 
VMAT PSPT IMPT VMAT PSPT IMPT VMAT PS IMPT 
1 15.2 7.1 9.1 3.9 3.0 2.5 0.247 0.068 0.046 
2 11.7 4.9 5.8 2.2 2.1 1.8 0.045 0.025 0.016 
3 6.2 3.4 3.8 0.8 0.7 0.7 0.004 0.001 0.001 
4 19.6 10.0 11.8 4.8 4.6 3.5 0.455 0.227 0.127 
5 16.2 7.7 10.6 2.9 3.5 3.0 0.143 0.103 0.082 
6 12.4 4.2 6.0 2.3 1.8 1.4 0.069 0.015 0.010 
7 9.6 3.6 4.9 1.9 1.5 1.3 0.028 0.010 0.007 
8 17.4 9.4 11.6 4.6 4.3 3.9 0.380 0.187 0.155 
9 7.8 4.8 4.6 1.6 2.0 1.4 0.023 0.022 0.009 
10 9.9 4.5 5.9 2.7 1.3 1.2 0.074 0.008 0.008 
11 11.7 6.0 6.8 3.1 2.7 2.3 0.117 0.047 0.034 
12 7.9 4.8 6.9 1.8 2.0 1.5 0.027 0.022 0.015 
13 14.5 8.4 8.9 2.8 3.4 2.1 0.130 0.111 0.034 
Average 12.3 6.1 7.4 2.7 2.5 2.1 0.13 0.07 0.04 
SD 4.1 2.2 2.7 1.2 1.2 1.0 0.14 0.07 0.05 
p-value - 
VMAT
-PSPT 
VMAT-
IMPT - 
VMAT-
PSPT 
VMAT-
IMPT - 
VMAT-
PSPT 
VMAT
-IMPT 
t-test - <<0.05 <<0.05 - 0.2 0.0005 - 0.008 0.006 
WSR -  0.001 0.001 -  0.2  0.02 -  0.001 0.001 
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Table 3.21 Calculated risk of necrosis using the linear quadratic (LQ) and linear plateau 
(LP) model compared to baseline risk calculated using the Lyman Kutcher Burman 
model for all patients. Descriptive statistics include the mean value with standard 
deviation (SD), and the p-value for the student t-test and Wilcoxon signed rank (WSR) 
test. 
Patient 
index 
LQ(%) LP(%) Baseline LKB(%) 
VMAT PSPT IMPT VMAT PSPT IMPT VMAT PSPT IMPT 
1 9.7 5.5 5.4 25.2 9.6 16.0 0.25 0.07 0.05 
2 6.1 3.8 3.7 22.5 6.5 9.6 0.04 0.02 0.02 
3 2.9 1.9 1.9 12.9 6.2 7.9 0.004 0.001 0.001 
4 12.3 7.9 7.4 32.4 13.0 19.9 0.45 0.23 0.13 
5 9.1 6.1 6.5 29.0 10.0 18.3 0.14 0.10 0.08 
6 7.1 3.3 3.3 22.1 5.6 11.3 0.07 0.01 0.01 
7 5.0 2.8 3.0 18.9 4.9 8.4 0.03 0.01 0.01 
8 11.1 7.4 7.6 28.7 12.1 19.1 0.38 0.19 0.15 
9 4.7 3.7 3.0 13.3 6.4 7.3 0.0230 0.0216 0.0090 
10 6.3 3.0 3.2 16.3 7.2 10.9 0.0736 0.0076 0.0078 
11 7.5 4.7 4.6 19.1 7.8 10.7 0.117 0.047 0.034 
12 4.8 3.7 4.1 13.3 6.4 12.1 0.027 0.022 0.015 
13 8.7 6.4 5.1 24.8 11.2 16.2 0.130 0.111 0.034 
Average 7.3 4.6 4.5 21.4 8.2 12.9 0.13 0.07 0.04 
SD 2.7 1.9 1.8 6.4 2.7 4.4 0.14 0.07 0.05 
p-value - 
VMAT-
PSPT 
VMAT-
IMPT - 
VMAT-
PSPT 
VMAT-
IMPT - 
VMAT-
PSPT 
VMAT-
IMPT 
t-test - 0.000002 0.000002 - 0.0000002 0.0000009 - 0.008 0.006 
WSR - 0.001  0.001 - 0.001 0.001 - 0.001 0.001 
 
The ratio of risk from alternative risk model calculations can bee seen in Table 
3.22 and 3.23 compared to the baseline ratio of risk calculated using the LKB model. 
These results are also displayed in Figure 3.20 and 3.21 for PSPT and IMPT, 
respectively. For all models the ratio was calculated and compared to 1 using the 
Wilcoxon signed rank test.  For almost all of the alternative risk models the calculated the 
ratios of risk were significantly less than 1. Again the exception was the PSPT plans 
calculated using the LT model: the average ratio of risk for these plans was 0.9 + 0.2 and 
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4 of the 13 plans had a ratio above 1. The ratio of risk was not significantly less than one 
for these plans. There was also a single IMPT plan calculated using the LT model that 
had a ratio of risk above 1, but the average ratio of risk were still found to be significantly 
less than one.   
Table 3.22 Ratio of risk calculated with the linear non threshold (LNT) and linear 
threshold (LT) models compared to the baseline ratio of risk calculated with the LKB 
model for all patients. Descriptive statistics include the mean value with standard 
deviation (SD), and the p-value for the Wilcoxon signed rank (WSR) test. 
Patient 
index 
rLNT rLT rRisk baseline 
PSPT 
/VMAT 
IMPT 
/VMAT 
PSPT 
/VMAT 
IMPT 
/VMAT 
PSPT 
/VMAT 
IMPT 
/VMAT 
1 0.47 0.60 0.77 0.64 0.28 0.19 
2 0.42 0.50 0.98 0.81 0.55 0.36 
3 0.55 0.61 0.82 0.83 0.39 0.39 
4 0.51 0.60 0.94 0.72 0.50 0.28 
5 0.48 0.66 1.22 1.05 0.72 0.57 
6 0.34 0.48 0.79 0.63 0.22 0.14 
7 0.38 0.51 0.81 0.69 0.35 0.27 
8 0.54 0.67 0.93 0.85 0.49 0.41 
9 0.62 0.59 1.21 0.85 0.94 0.39 
10 0.46 0.59 0.48 0.45 0.10 0.11 
11 0.51 0.59 0.87 0.73 0.40 0.29 
12 0.61 0.88 1.12 0.87 0.80 0.54 
13 0.58 0.62 1.23 0.78 0.85 0.26 
Average 0.5 0.6 0.9 0.8 0.5 0.3 
SD 0.1 0.1 0.2 0.1 0.3 0.1 
WSR 0.001 0.002 0.1 0.02 0.002 0.002 
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Table 3.23 Ratio of risk calculated with the linear quadratic (LQ) and linear plateau (LP) 
models compared to the baseline ratio of risk calculated with the LKB model for all 
patients. Descriptive statistics include the mean value with standard deviation (SD), and 
the p-value for the Wilcoxon signed rank (WSR) test. 
Patient 
index 
rLQ rLP rRisk baseline 
PSPT 
/VMAT 
IMPT 
/VMAT 
PSPT 
/VMAT 
IMPT 
/VMAT 
PSPT 
/VMAT 
IMPT 
/VMAT 
1 0.56 0.56 0.38 0.63 0.28 0.19 
2 0.62 0.60 0.29 0.43 0.55 0.36 
3 0.64 0.64 0.48 0.61 0.39 0.39 
4 0.64 0.61 0.40 0.61 0.50 0.28 
5 0.66 0.71 0.35 0.63 0.72 0.57 
6 0.46 0.47 0.25 0.51 0.22 0.14 
7 0.55 0.59 0.26 0.44 0.35 0.27 
8 0.67 0.68 0.42 0.67 0.49 0.41 
9 0.79 0.64 0.48 0.55 0.94 0.39 
10 0.47 0.51 0.44 0.67 0.10 0.11 
11 0.63 0.62 0.41 0.56 0.40 0.29 
12 0.77 0.84 0.48 0.91 0.80 0.54 
13 0.74 0.59 0.45 0.66 0.85 0.26 
Average 0.6 0.6 0.4 0.6 0.5 0.3 
SD 0.1 0.1 0.1 0.1 0.3 0.1 
WSR 0.001 0.001 0.001 0.001 0.002 0.002 
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Figure 3.20 The ratio of risk of necrosis for PSPT plans compared to VMAT calculated 
with the linear no threshold (LNT), linear threshold (LT), linear quadratic (LQ), and 
linear plateau (LP) models compared to the baseline ratio of risk (red circles) calculated 
with the Lyman Kutcher Burman (LKB) model.  
 
 
Figure 3.21 The ratio of risk of necrosis for IMPT plans compared to VMAT calculated 
with the linear non threshold (LNT), linear threshold (LT), linear quadratic (LQ), and 
linear plateau (LP) models compared to the baseline ratio of risk (red circles) calculated 
with the Lyman Kutcher Burman (LKB) model.  
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Chapter 4 Discussion 
The objectives of this study were to calculate the predicted risk of radiation 
induced necrosis based on treatment plans for a cohort of pediatric patients using existing 
dose-risk models and to estimate the uncertainties in the calculated risk based on setup 
errors, proton range errors, and choice of risk model. The results show that both passively 
scattered proton therapy (PSPT) and intensity modulated proton therapy (IMPT) give a 
lower predicted risk of radiation induced necrosis than photon plans constructed using 
volumetric modulated arc therapy (VMAT). Sensitivity analysis reinforces the findings 
that protons confer a lower risk of radiation-induced necrosis. 
4.1 Outcomes of specific aim one 
 
Specific aim one was to evaluate and compare VMAT, PSPT and IMPT plans on 
the basis of dosimetric endpoints for the PTV and whole brain. For glioma patients (1-8) 
the planning goal was 95% of the prescription dose to be given to 95% of the volume.  
Most plans met this goal for all modalities of treatment plans with only 1 of the VMAT 
plans and 2 of the passive scatter plans falling below this value. Some studies have also 
found similar coverage between proton and with IMRT photon plans while others have 
shown better coverage for protons when compared against photon conformal radiation 
therapy (Bolsi et al., 2003; Merchant et al., 2008; Baumert et al., 2004). 
Ependymoma plans resulted in worse coverage than the glioma plans. Three of 
the PSPT plans and one of the IMPT plans fell below the planning goal of 90% of the 
prescription dose to 95% of the volume.  However these plans were still clinically 
acceptable.  It is important to note that with the location of the treatment volume there 
was some overlap in the brainstem.  For this reason the PTV planning goal was sacrificed 
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in most cases since the constraint on the dose to the brainstem was considered as the 
paramount objective.  
The minimum, maximum and mean dose metrics for the PTV were compared. 
The results typically showed a higher overall maximum dose for proton plans compared 
to VMAT, and a lower minimum dose. The mean dose showed no significant difference 
between PSPT, VMAT, or IMPT plans. 
Passively scattered proton therapy (PSPT) plans tended to be much less 
homogeneous than either VMAT while IMPT plans showed no difference from VMAT in 
the PTV dose homogeneity. Contrary to our study Bolsi et al. (2003) found that passively 
scattered proton had better homogeneity than photons.  However their comparison was 
with 3D conformal radiation therapy and not with VMAT, which typically has better 
conformity. Howell et al. (2012) also found that  photon plans were found to have greater 
dose heterogeneity than passively scattered proton therapy (PSPT) for medulloblastoma 
Again, their study was not comparing PSPT to VMAT and additionally they used D5% 
and D95% for homogeneity calculation compared with D2% and D98% used in our study. 
Kozak et al. (2009) did compare protons to intensity modulated radiation therapy (IMRT) 
which has a similar dose delivery to VMAT and found that homogeneity was comparable 
between modalities. 
The results of conformity showed that while PSPT and VMAT were similar, 
IMPT resulted in increase dose conformity to the PTV. Merchant et al. (2008) also found 
better conformity over photon therapy when using an active scanning technique for a 
variety of different brain cancer treatments. However the specific photon modality that 
was used for treatment was not specified in that study. Baumert et al. (2001) also found 
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increase conformity for IMPT and PSPT for irregularly shaped tumors  compared to 
intensity modulated stereotactic radiotherapy but conformity was comparable between 
modalities for large concentric treatment volumes.  
The dose metrics for the whole brain showed a reduction in the mean dose but an 
increased maximum dose for protons compared to VMAT. The reduction of the mean 
dose was expected since the protons have been shown to reduce the volume of 
surrounding tissue irradiated compared to photon therapies, thereby reducing the mean 
dose. Kozak et al. (2009) also found this reduction in the mean dose to surrounding 
normal tissues. The increase in the maximum dose is likely due to tissue heterogeneities 
(Urie et al., 1984). Baumert et al. (2004) and Kozak et al. (2009)also found an increase in 
the maximum dose from protons compared to photon therapies. 
The VMAT plans had much larger volumes of the brain that were irradiated to a 
low doses of 5 and 10 Gy RBE than the proton plans. Other studies have found similar 
results of normal tissue sparing for brain treatments (Fuss et al., 1999; Lin et al., 2000; 
Bolsi et al., 2003; Baumert et al., 2004; St. Clair et al., 2004; Merchant et al., 2008). 
However, the fractional volume of the brain receiving high dose (V50Gy-RBE, V52Gy-RBE, 
and V56Gy-RBE) showed very little difference between planning modalities. These volume 
metrics were compared in a study by Murphy et al. (2012) and determined to be an 
indicator of risk for radiation necrosis.  The volumes irradiated to the 50, 52, and 56 Gy 
levels were in most cases below the volume indicated by Murphy et al. (2012) to incur a 
3.7% risk of necrosis. A more important indicator presented by that study was the 
infratentorial volumes irradiated and may be of interest in future studies for our 
ependymoma patients with assigned tumors located in the posterior fossa. Murphy et al. 
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(2012) found that the volume of the infratentorial brain that received 50, 52, and 54 Gy-
RBE was a significant predictor for radiation necrosis.  
4.2 Outcome for specific aim two 
Specific aim two was to predict the risk of radiation necrosis for each treatment 
plan and the mean ratio of risk for a cohort of pediatric patients with ependymoma and 
glioma. This risk was calculated using LKB NTCP model. Result clearly showed that 
there is a reduction in the NTCP for both proton modalities relative to that for VMAT. 
However, the low level of risk calculated by the LKB model was largely unexpected. 
Previous studies have stated that the incidence of radiation necrosis is related to the total 
dose given, fraction size and irradiated volume (Ruben et al., 2006; Lawrence et al., 
2010; Fink et al., 2012). These studies reported an approximate incidence of 3% for 
prescribed dose of 50-60 Gy in 1.8-2.5 Gy/fraction for patients treated at their clinics. 
Our results were approximately 10% lower on average. Despite this discrepancy the 
mean rNTCP for PSPT and IMPT plans were 0.51 and 0.32, respectively, across the 
entire cohort. The Wilcoxon signed rank test was performed for these results confirming 
that both proton modalities (PSPT and IMPT) statistically significantly reduce the 
predicted risk of radiation-induced necrosis for our sample of pediatric patients. 
4.3 Outcome of specific aim three 
 
 Specific aim three was to perform sensitivity analysis to determine if the baseline 
risk is dependent on setup error, proton range uncertainties and risk model selection. 
Simulated setup and range errors were performed by shifting the plan isocenter and 
introducing calibration curve errors, respectively, for 2 patients. Alternative risk model 
assessment was performed for all patients and compared to the baseline risk  
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Plan specific isocenter shifts resulted in a reduction of PTV coverage as seen by a 
reduction in the dose to 95% of the PTV (D95%) and the mean dose to the PTV for both 
patient 5 and 12. This result was expected for a simulated patient setup error since we are 
moving the isocenter away from the center of the PTV resulting in a slight miss in the 
target. The minimum and maximum dose to both the PTV and brain fluctuated with 
isocenter shift but tended to have much greater changes in the proton plans compared to 
VMAT plans. Overall the changes in the dose metric for isocenter shifts were minimal 
and resulted in minor variations in NTCP and the ratio of NTCP compared to the nominal 
plans.  PSPT plans seemed to be slightly more susceptible to setup error, which is likely 
due to the single beam arrangement that was used in most of the PSPT plans. 
Range errors from shifts in the CT calibration curve resulted in changes to the 
relative risk of necrosis (rNTCP) across proton planning modalities. An increase of 10% 
in the calibration curve resulted in reduction of the proton range within the target as well 
as within the brain and a reduction in the risk.  A decrease in the calibration curve would 
have the opposite effect and an increase in the risk of necrosis was the result. This is in 
accordance with calibration reports for HU-proton stopping power in the 
literature.(Schneider et al., 1996; Urie et al., 1984; Schaffner and Pedroni, 1998; Moyers 
et al., 2001)  Additionally a 10% shift in the calibration curve is unlikely and is at the 
high end of what might be expected for actual range uncertainty. Even with such a large 
shift all of the proton NTCP values are still less than or equal to VMAT NTCP resulting 
in a rNTCP of less than 1 for all range errors. 
The choice of risk model used can cause large variations in the NTCP results as 
seen with the alternate risk models chosen in this paper. Most alternative models we 
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considered showed a reduction in the predicted risk when PSPT or IMPT was used 
instead of VMAT. Unfortunately, there are very few models to choose from with necrosis 
as an endpoint that take all variables into account. Our findings clearly revealed that 
LKB, LNT, and LP models were strongly influenced by the volume of the brain 
irradiated at low dose. And although volumes receiving low dose may increase the 
chance of developing necrosis we believe that necrosis is likely a deterministic effect 
with a threshold dose and that the high dose region may strongly impact the initial 
necrotic incident. Additionally, the linear threshold (LT) model had a threshold at about 
43 Gy-RBE and resulted in risks of necrosis of approximately 1-5% as seen in Table 
3.20, which better agreed with retrospective studies of similar prescriptions and 
fractionation and had observed rates of necrosis of approximately 3-5%. (Ruben et al., 
2006; Murphy et al., 2012; Lee et al., 2011)  
4.4 Implications of this study 
The risk of radiation necrosis is of particular interest in pediatric patients with 
brain cancer because the current cure rates for these cancers are high and life expectancy 
is long. Additionally, with the second highest incidence among pediatrics, brain cancer is 
more prevalent than many other cancers and necrosis is severe side effect of treatment 
that is potentially fatal. 
The findings of this study indicate that choosing either PSPT or IMPT over 
VMAT when treating some pediatric brain cancer patients can reduce the predicted risk 
of radiation necrosis. The ratio of risk was sensitive to proton range uncertainty but still 
showed significant risk reduction for proton plans over VMAT. Additionally the choice 
of risk model had little impact on the ratio of risk for necrosis except for the linear 
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threshold (LT) model, which in some cases resulted in ratios of risk greater than one. The 
LT model reduces the impact of the low dose volumes in risk calculation by instituting a 
threshold dose, which result in calculation of risk only in the high dose region. 
4.5 Strengths and limitations of this study 
This study had several strengths. Among them was the use of clinically realistic 
data from 13 pediatric patients. Additionally all plans were planned by a single individual 
and approved by a single board certified radiation oncologist to reduce bias between 
plans and give an accurate comparison. Patient plans were also investigated for 
uncertainties such as setup error and range error to determine if the rNTCP for radiation 
necrosis was sensitive to shifts and proton range errors compared to the nominal beam 
delivery.  Finally the LKB NTCP model was used as a baseline measurement for risk of 
necrosis, and alternative risk models were examined too. 
Some limitations of this study include the small patient cohort.  Although we used 
real patient data the time resource constraints made it difficult include a larger pediatric 
patient population. However, with a cohort of 13 pediatric patients, statistical comparison 
was still applicable and largely overcome this limitation.  
Another limitation was risk model selection. Little has been done to develop a 
model that accurately predicts radiation necrosis or improves upon the existing LKB 
NTCP model. Lawrence et al. (2010) in their recent study as part of a Quantitative 
Analyses of Normal Tissue Effects in the Clinic (QUANTEC) stated that the data used 
for the data that the LKB model is based off of was likely conservative but they did not 
propose a new model. Additionally, recent studies such as the one by Murphy et al. 
(2012) reported higher incidence than the risk predicted by the LKB model in this 
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research. For these reason, a sensitivity analysis was performed to determine the effects 
of risk model selection on the ratio of normal tissue complication probability (rNTCP).  
4.6 Future work 
Future studies should investigate in greater detail the effects of proton range error 
on clinical acceptability and its effect on necrosis. Additionally there are some clinical 
alternatives for treatment that may increase the potential risk of necrosis from protons 
therapy (i.e. patch beams).  Maybe most importantly there is potential for development of 
a risk model that can better predict the risk of necrosis.  An important step in this process 
would be a better understanding of the patient history, pediatric and otherwise, that have 
been diagnosed with necrosis across a large population. Currently there is little 
information, or little shared, on the population of patients that have developed necrosis 
post irradiation from any institution. From this information a new analytical model for 
necrosis could be developed that might better predict the risk of RIN. 
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Chapter 5 Conclusion 
This study demonstrated that proton plans (PSPT and IMPT) were capable of 
reducing the predicted risk of necrosis.  IMPT overall had improved conformity and 
similar homogeneity to VMAT plans with similar PTV coverage while PSPT had similar 
conformity to VMAT and worse homogeneity and typically worse coverage of the PTV 
compared to VMAT.  VMAT plans delivered low dose to a considerably greater volume 
of the brain.  
Calculated NTCP resulted in a fairly low risk of necrosis to the brain however the 
ratio of risk showed a considerable reduction when using either PSPT or IMPT over 
VMAT. The effects of setup and range uncertainties did have an effect on the calculated 
rNTCP but did not affect the qualitative findings that both proton modalities confer a 
reduced risk of necrosis. For all alternative models, except the linear threshold (LT) 
model, the ratio of risk was insensitive to the selection of risk model selection and upheld 
the findings that PSPT and IMPT confer a reduction in the risk of radiation necrosis. For 
these reasons we must reject the null hypothesis and conclude that, for our cohort of 
pediatric patients, proton plans resulted in a reduction in the predicted risk of radiation 
induced necrosis of the brain. 
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Appendix A: Isodose Distributions 
 
Figure A.1 Isodose distributions for VMAT(a), PSPT (b), and IMPT (c) for patient 1.  
The slice location is through the planning isocenter and displayed on the sagittal view (d) 
by a yellow line. 
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Figure A.2 Isodose distributions for VMAT(a), PSPT (b), and IMPT (c) for patient 2.  
The slice location is through the planning isocenter and displayed on the sagittal view (d) 
by a yellow line. 
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Figure A.3 Isodose distributions for VMAT(a), PSPT (b), and IMPT (c) for patient 3.  
The slice location is through the planning isocenter and displayed on the sagittal view (d) 
by a yellow line. 
 80 
 
Figure A.4 Isodose distributions for VMAT(a), PSPT (b), and IMPT (c) for patient 4.  
The slice location is through the planning isocenter and displayed on the sagittal view (d) 
by a yellow line. 
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Figure A.5 Isodose distributions for VMAT(a), PSPT (b), and IMPT (c) for patient 5.  
The slice location is through the planning isocenter and displayed on the sagittal view (d) 
by a yellow line. 
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Figure A.6 Isodose distributions for VMAT(a), PSPT (b), and IMPT (c) for patient 6.  
The slice location is through the planning isocenter and displayed on the sagittal view (d) 
by a yellow line. 
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Figure A.7 Isodose distributions for VMAT(a), PSPT (b), and IMPT (c) for patient 7.  
The slice location is through the planning isocenter and displayed on the sagittal view (d) 
by a yellow line. 
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Figure A.8 Isodose distributions for VMAT(a), PSPT (b), and IMPT (c) for patient 8.  
The slice location is through the planning isocenter and displayed on the sagittal view (d) 
by a yellow line. 
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Figure A.9 Isodose distributions for VMAT(a), PSPT (b), and IMPT (c) for patient 9.  
The slice location is through the planning isocenter and displayed on the sagittal view (d) 
by a yellow line. 
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Figure A.10 Isodose distributions for VMAT(a), PSPT (b), and IMPT (c) for patient 10.  
The slice location is through the planning isocenter and displayed on the sagittal view (d) 
by a yellow line. 
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Figure A.11 Isodose distributions for VMAT(a), PSPT (b), and IMPT (c) for patient 11.  
The slice location is through the planning isocenter and displayed on the sagittal view (d) 
by a yellow line. 
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Figure A.12 Isodose distributions for VMAT(a), PSPT (b), and IMPT (c) for patient 12.  
The slice location is through the planning isocenter and displayed on the sagittal view (d) 
by a yellow line. 
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Figure A.13 Isodose distributions for VMAT(a), PSPT (b), and IMPT (c) for patient 13.  
The slice location is through the planning isocenter and displayed on the sagittal view (d) 
by a yellow line. 
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Appendix B: Patient DVH 
 
Figure B.1 DVH for patient 1 
 
Figure B.2 DVH for patient 2 
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Figure B.3 DVH for patient 3 
 
Figure B.4 DVH for patient 4 
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Figure B.5 DVH for patient 5 
 
Figure B.6 DVH for patient 6 
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Figure B.7 DVH for patient 7 
 
Figure B.8 DVH for patient 8 
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Figure B.9 DVH for patient 9 
 
Figure B.10 DVH for patient 10 
 95 
 
Figure B.11 DVH for patient 11 
 
Figure B.12 DVH for patient 12 
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Figure B.13 DVH for patient 13 
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Appendix C: Isocenter shift DVH 
 
Figure C.1 DVH for patient 5 VMAT isocenter shift in the x direction 
 
Figure C.2 DVH for patient 5 VMAT isocenter shift in the y direction 
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Figure C.3 DVH for patient 5 VMAT isocenter shift in the z direction 
 
Table C.1 Mean, maximum and minimum doses to the PTV for VMAT isocenter shifts in 
patient 5 
VMAT 
Dmean  
(Gy-RBE) 
Dmax  
(Gy-RBE) 
Dmin  
(Gy-RBE)  
D95%  
(Gy-RBE) 
nominal 52.5 57.5 31.7 48.8 
x+1cm 52.2 57.3 40.4 48.3 
x-1cm 51.2 57.7 25.1 42.4 
y+1cm 51.0 57.4 15.1 41.3 
y-1cm 52.1 57.2 37.5 47.4 
z+1cm 49.2 57.6 14.0 32.1 
z-1cm 51.9 57.2 24.2 45.2 
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Table C.2 The mean and maximum doses to the brain for VMAT isocenter shifts in 
patient 5. 
VMAT 
Dmean  
(Gy-RBE) 
Dmax  
(Gy-RBE) 
Nominal 23.2 57.5 
x+1cm 24.2 57.3 
x-1cm 21.8 57.7 
y+1cm 23.7 57.7 
y-1cm 22.1 57.9 
z+1cm 23.1 57.7 
z-1cm 21.7 57.9 
 
Table C.3 Percentage volume of the brain receiving 5, 10, 50, 52, and 56 Gy-RBE and 
normal tissue complication probability for VMAT isocenter shifts in patient 5. 
VMAT 
V5Gy-RBE 
(%) 
V10Gy-RBE 
(%) 
V50Gy-RBE 
(%) 
V52Gy-RBE 
(%) 
V56Gy-RBE 
(%) NTCP(%) 
Nominal 82.2 73.7 13.1 8.6 0.2 0.14 
x+1cm 82.4 75.1 13.0 8.4 0.20 0.159 
x-1cm 81.6 70.9 12.6 8.8 0.34 0.1163 
y+1cm 82.2 73.9 13.2 8.7 0.29 0.155 
y-1cm 81.7 72.4 12.4 7.7 0.08 0.1159 
z+1cm 82.2 73.7 13.1 8.5 0.28 0.1434 
z-1cm 77.1 69.0 12.6 8.1 0.10 0.1176 
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Figure C.4 DVH for patient 5 PSPT plans with an isocenter shift in the x direction. 
 
Figure C.5 DVH for patient 5 PSPT plans with an isocenter shift in the y direction. 
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Figure C.6 DVH for patient 5 PSPT plans with an isocenter shift in the z direction. 
 
Table C.4 PTV results for passively scattered proton therapy isocenter shifts for patient 5. 
PSPT 
Dmean  
(Gy-RBE) 
Dmax  
(Gy-RBE) 
Dmin  
(Gy-RBE)  
D95%  
(Gy-RBE) 
nominal 52.9 63.2 0.5 49.5 
x+1cm 52.9 63.7 2.1 44.9 
x-1cm 51.7 62.5 0.1 38.4 
y+1cm 50.2 63.2 0.0 18.8 
y-1cm 51.3 61.8 0.5 33.0 
z+1cm 45.6 62.7 0.0 1.6 
z-1cm 48.4 59.2 0.1 7.7 
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Table C.5 Mean and maximum doses to the brain for PSPT isocenter shifts in patient 5. 
PSPT 
Dmean 
 (Gy-RBE) 
Dmax  
(Gy-RBE) 
Nominal 10.0 63.2 
x+1cm 9.8 63.7 
x-1cm 10.0 62.5 
y+1cm 10.1 63.8 
y-1cm 9.7 62.5 
z+1cm 10.2 62.7 
z-1cm 9.1 62.4 
 
Table C.6 Percentage volume of the brain receiving 5, 10, 50, 52, and 56Gy-RBE for 
PSPT isocenter shifts in patient 5. 
PSPT 
V5Gy-RBE 
(%) 
V10Gy-RBE 
(%) 
V50Gy-RBE 
(%) 
V52Gy-RBE  
(%) 
V56Gy-RBE 
(%) NTCP(%) 
Nominal 22.4 21.0 14.1 13.0 0.3 0.10 
x+1cm 22.0 20.6 14.0 13.0 0.45 0.107 
x-1cm 22.8 21.3 14.2 12.9 0.23 0.098 
y+1cm 22.8 21.3 14.2 13.1 0.39 0.109 
y-1cm 21.8 20.4 13.8 12.6 0.22 0.092 
z+1cm 23.1 21.6 14.3 13.1 0.34 0.108 
z-1cm 20.3 19.0 13.1 12.1 0.25 0.081 
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Figure C.7 DVH for patient 5 IMPT plan with a shift in the x direction 
 
Figure C.8 DVH for patient 5 IMPT plan with a shift in the y direction. 
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Figure C.9 DVH for patient 5 IMPT plan with a shift in the z direction. 
Table C.7 PTV results for IMPT isocenter shift for patient 5. 
IMPT 
Dmean  
(Gy-RBE) 
Dmax  
(Gy-RBE) 
Dmin  
(Gy-RBE)  
D95%  
(Gy-RBE) 
nominal 54.1 57.2 39.2 52.8 
x+1cm 52.7 66.1 14.5 39.5 
x-1cm 51.6 61.8 23.2 42.1 
y+1cm 52.7 67.5 16.3 41.2 
y-1cm 52.4 60.1 22.9 42.2 
z+1cm 50.9 61.9 7.4 32.8 
z-1cm 50.2 56.8 3.3 34.6 
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Table C.8 Mean and Maximum doses to the brain for IMPT isocenter shifts in patient 5. 
IMPT 
Dmean  
 (Gy-RBE) 
Dmax  
(Gy-RBE) 
Nominal 15.0 58.0 
x+1cm 15.0 67.9 
x-1cm 14.6 64.5 
y+1cm 15.1 67.6 
y-1cm 14.6 64.2 
z+1cm 15.0 73.9 
z-1cm 14.4 58.8 
 
Table C.9 Percentage volume of the brain receiving 5, 10, 50, 52, and 56Gy-RBE for 
IMPT isocenter shifts in patient 5. 
IMPT 
V5Gy-RBE 
(%) 
V10Gy-RBE 
(%) 
V50Gy-RBE 
(%) 
V52Gy-RBE  
(%) 
V56Gy-RBE 
(%) NTCP(%) 
Nominal 53.3 47.5 12.0 10.8 0.0 0.08 
x+1cm 54.6 48.4 10.6 9.6 2.22 0.082 
x-1cm 51.6 46.4 10.9 8.8 0.30 0.059 
y+1cm 53.7 47.9 11.4 9.9 1.11 0.087 
y-1cm 52.9 47.2 10.8 9.4 0.60 0.064 
z+1cm 51.4 46.0 12.1 10.9 1.71 0.108 
z-1cm 53.6 47.6 10.1 8.7 0.20 0.055 
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Figure C.10 DVH for patient 12 VMAT plans with an isocenter shift in the x direction. 
 
Figure C.11 DVH for patient 12 VMAT plans with an isocenter shift in the y direction. 
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Figure C.12 DVH for patient 12 VMAT plans with an isocenter shift in the z direction. 
 
Table C.10 PTV result for patient 12 VMAT isocenter shifts. 
VMAT 
Dmean  
(Gy-RBE) 
Dmax  
(Gy-RBE) 
Dmin  
(Gy-RBE)  
D95%  
(Gy-RBE) 
Nominal 53.3 54.7 42.8 50.6 
x+1cm 52.73 55.253 35.85 46.9 
x-1cm 52.4 55.4 31.9 45.1 
y+1cm 51.0 55.4 27.5 39.1 
y-1cm 53.4 54.8 44.2 50.9 
z+1cm 50.3 54.4 17.0 33.8 
z-1cm 47.7 55.0 7.5 21.2 
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Table C.11 Mean and maximum doses to the brain for VMAT isocenter shifts in patient 
12. 
VMAT 
Dmean   
(Gy-RBE) 
Dmax    
(Gy-RBE) 
Nominal 11.1 54.7 
x+1cm 11.2 55.5 
x-1cm 10.7 55.8 
y+1cm 10.8 55.4 
y-1cm 11.0 54.8 
z+1cm 13.8 54.4 
z-1cm 7.7 55.0 
 
Table C.12 Percentage volume of the brain receiving 5, 10, 50, 52, and 56Gy-RBE for 
PSPT isocenter shifts in patient 12. 
PSPT 
V5Gy-RBE 
(%) 
V10Gy-RBE 
(%) 
V50Gy-RBE 
(%) 
V52Gy-RBE  
(%) 
V56Gy-RBE 
(%) NTCP (%) 
Nominal 14.2 13.3 8.3 7.1 0.3 0.022 
x+1cm 14.6 13.6 8.4 7.4 0.32 0.024 
x-1cm 13.7 12.8 7.7 6.6 0.19 0.017 
y+1cm 14.6 13.7 8.3 7.1 0.19 0.021 
y-1cm 13.6 12.7 7.8 6.9 0.31 0.019 
z+1cm 17.3 16.1 9.1 7.9 0.26 0.031 
z-1cm 10.0 9.4 6.1 5.3 0.19 0.008 
 
 109 
 
Figure C.13 DVH for patient 12 PSPT plans with an isocenter shift in the x direction. 
 
Figure C.14 DVH for patient 12 PSPT plans with an isocenter shift in the y direction. 
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Figure C.15 DVH for patient 12 PSPT plans with an isocenter shift in the z direction. 
 
Table C.13 Percentage volume of the brain receiving 5, 10, 50, 52, and 56Gy-RBE for 
PSPT isocenter shifts in patient 12. 
VMAT 
V5Gy-RBE 
 (%) 
V10Gy-RBE 
(%) 
V50Gy-RBE 
(%) 
V52Gy-RBE 
(%) 
V56Gy-RBE 
(%) NTCP 
Nominal 31.2 27.9 8.0 6.4 0.0 0.027 
x+1cm 31.2 28.0 8.3 6.8 0.00 0.031 
x-1cm 31.1 27.6 7.7 6.4 0.00 0.0244 
y+1cm 30.9 27.5 8.1 6.6 0.00 0.03 
y-1cm 31.3 27.9 7.4 6.0 0.00 0.0228 
z+1cm 41.8 37.5 8.1 6.1 0.00 0.0343 
z-1cm 21.2 18.3 6.1 5.1 0.00 0.0112 
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Table C.14 PTV results for passively scattered proton therapy isocenter shifts for patient 
12. 
PSPT 
Dmean  
(Gy-RBE) 
Dmax  
(Gy-RBE) 
Dmin  
(Gy-RBE)  
D95%  
(Gy-RBE) 
Nominal 52.7 60.0 3.5 46.5 
x+1cm 49.5 59.5 0.0 16.6 
x-1cm 50.7 60.0 0.7 29.8 
y+1cm 49.2 59.0 0.0 17.2 
y-1cm 51.0 60.7 0.7 28.8 
z+1cm 48.2 60.5 0.5 16.8 
z-1cm 42.9 59.2 0.1 2.1 
 
Table C.15 Mean and maximum doses to the brain for PSPT isocenter shifts in patient 12. 
PSPT 
Dmean  
(Gy-RBE) 
Dmax  
(Gy-RBE) 
Nominal 6.2 60.3 
x+1cm 6.4 60.2 
x-1cm 5.9 60.5 
y+1cm 5.9 61.2 
y-1cm 6.3 59.6 
z+1cm 7.3 60.5 
z-1cm 4.4 60.7 
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Figure C.16 DVH for patient 12 IMPT plans with an isocenter shift in the x direction. 
 
Figure C.17 DVH for patient 12 IMPT plans with an isocenter shift in the y direction. 
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Figure C.18 DVH for patient 12 IMPT plans with an isocenter shift in the z direction. 
 
Table C.16 PTV results for IMPT isocenter shifts in patient 12. 
IMPT 
Dmean  
(Gy-RBE) 
Dmax  
(Gy-RBE) 
Dmin  
(Gy-RBE)  
D95%  
(Gy-RBE) 
Nominal 53.5 58.2 32.8 50.2 
x+1cm 51.5 66.6 13.9 38.1 
x-1cm 51.0 69.6 9.1 38.8 
y+1cm 49.4 60.4 2.2 23.9 
y-1cm 49.7 59.9 7.9 26.4 
z+1cm 50.4 60.6 9.0 34.6 
z-1cm 49.2 55.9 10.1 32.7 
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Table C.17 Mean and maximum doses to the brain for IMPT isocenter shifts in patient 
12. 
IMPT 
Dmean  
(Gy-RBE) 
Dmax  
(Gy-RBE) 
Nominal 9.9 60.9 
x+1cm 9.8 69.0 
x-1cm 9.5 69.8 
y+1cm 9.8 63.6 
y-1cm 9.4 62.8 
z+1cm 11.1 64.1 
z-1cm 8.1 58.4 
 
Table C.18 Percentage volume of the brain receiving 5, 10, 50, 52, and 56Gy-RBE for 
IMPT isocenter shifts in patient 12. 
IMPT 
V5Gy-RBE 
(%) 
V10Gy-RBE 
(%) 
V50Gy-RBE 
(%) 
V52Gy-RBE  
(%) 
V56Gy-RBE 
(%) NTCP 
Nominal 33.4 29.4 6.4 5.6 0.0 0.015 
x+1cm 33.6 29.5 5.6 4.7 1.06 0.014 
x-1cm 32.5 28.8 5.0 4.1 0.81 0.012 
y+1cm 32.7 29.0 6.4 5.5 0.35 0.016 
y-1cm 32.2 28.4 5.7 4.7 0.35 0.012 
z+1cm 37.6 33.0 6.9 6.1 0.39 0.021 
z-1cm 27.7 24.5 5.0 4.2 0.02 0.007 
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